

647732

P/00/008 28/5/91
Section 29(1)
Regulation 3.1 (2)

AUSTRALIA

Patents Act 1990

NOTICE OF ENTITLEMENT

(To be filed before acceptance)

We, Jeffrey S. RUBIN
of 2020 BALTIMORE ROAD, APT, K-44
ROCKVILLE, MARYLAND 20851
U S A

of Paul W. FINCH
9306 HOLLAND AVENUE
BETHESDA, MARYLAND 20814
U S A

of Stuart A. AARONSON
1006 HARRIMAN STREET
GREAT FALLS, VIRGINIA 22066
U S A

being the applicants and nominated persons in respect of Application No. 50496/90, state the following:-

Part 1

The persons nominated for the grant of the patent are the actual inventors and we would be entitled under Section 15(1)(a) to have a patent granted to us, in respect of the invention.

Parts 2 and 3

Not Applicable


Part 4

The persons nominated for the grant of the patent are the applicants of the basic application listed in the declaration under Article 8 of the PCT.

The basic application listed in the declaration under Article 8 of the PCT is the first application made in a Convention country in respect of the invention.

Parts 5, 6 and 7

Not Applicable
GRIFFITH HACK & CO.



Patent Attorneys for and
on behalf of the applicants

28 JUL 1993

.....
Date



AU9050496

(12) PATENT ABRIDGMENT (11) Document No. AU-B-50496/90
(19) AUSTRALIAN PATENT OFFICE (10) Acceptance No. 647732

- (54) Title
DNA ENCODING A GROWTH FACTOR SPECIFIC FOR EPITHELIAL CELLS
- (51)⁵ International Patent Classification(s)
C07K 013/00 C07K 007/06 C07K 007/08 C07K 007/10
C12N 005/00 C12N 015/00 G01N 033/536
- (21) Application No. : 50496/90 (22) Application Date : 30.01.90
- (87) PCT Publication Number : WO90/08771
- (30) Priority Data
- (31) Number (32) Date (33) Country
304281 31.01.89 US UNITED STATES OF AMERICA
- (43) Publication Date : 24.08.90
- (44) Publication Date of Accepted Application : 31.03.94
- (71) Applicant(s)
JEFFREY S. RUBIN; PAUL W. FINCH; STUART A. AARONSON
- (72) Inventor(s)
JEFFREY S. RUBIN; PAUL W. FINCH; STUART A. AARONSON
- (74) Attorney or Agent
GRIFFITH HACK & CO, GPO Box 1285K, MELBOURNE VIC 3001

- (57) Discoveries are disclosed that show particular aspects or recombinant DNA technology can be used successfully to produce hitherto unknown human keratinocyte growth factor (KGF) protein free of other polypeptides. These proteins can be produced in various functional forms from spontaneously secreting cells or from DNA segments introduced into cells. These forms variously enable biochemical and functional studies of this novel protein as well as production of antibodies. Means are described for determining the level of expression of genes for the KGF protein, for example, by measuring mRNA levels in cells or by measuring antigen secreted in extracellular or body fluids.

CLAIM

1. A substantially pure human keratinocyte growth factor (KGF) protein or KGF-like protein having a molecular weight between 16 and 30 kDa as determined by migration in NaDodSO₄/PAGE, and having a specific activity of at least about 3.4×10^4 units per milligram of protein, wherein the minimum amount of growth factor sufficient to stimulate maximum mitogenic activity in cells of epithelial origin does not stimulate mitogenic activity in fibroblasts.

6. A chimeric KGF-like protein which comprises within a single polypeptide molecule functional domains of human KGF according to any one of claims 1 to 5 and at least one other polypeptide of the fibroblast growth factor family.

7. A chimeric KGF-like protein according to claim 6, wherein the fibroblast growth factor polypeptide is acidic fibroblast growth factor (aFGF).

8. A chimeric KGF-like protein according to claim 7, wherein the functional domain from KGF is defined by amino acid residues responsible for the preferential mitogenic activity of KGF on epithelial cells and the functional domain from aFGF that is defined by amino acid residues in that portion of aFGF that is homologous to the KGF sequence responsible for heparin sensitivity of KGF.



PCT

INTERNATIONAL APPLICATION

under INID Number (51) "International Patent Classification", replace the existing symbols by "C07K 3/18, 13/00, 7/06, 7/08, 7/10, C12N 5/00, 15/00, G01N 33/536"

COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : C07K 3/18, 13/00, 7/06, 7/08, 7/10 C12N 5/00, 15/00, G01N 33/536		A1	(11) International Publication Number: WO 90/08771 (43) International Publication Date: 9 August 1990 (09.08.90)
(21) International Application Number: PCT/US90/00418 (22) International Filing Date: 30 January 1990 (30.01.90) (30) Priority data: 304,281 31 January 1989 (31.01.89) US (71)(72) Applicants and Inventors: RUBIN, Jeffrey, S. [US/US]; 2020 Baltimore Road, Apt. K-44, Rockville, MD 20851 (US). FINCH, Paul, W. [GB/US]; 9306 Holland Avenue, Bethesda, MD 20814 (US). AARONSON, Stuart, A. [US/US]; 1006 Harriman Street, Great Falls, VA 22066 (US). (74) Agents: PATTERSON, Herbert, W. et al.; Finnegan, Henderson, Farabow, Garrett & Dunner, 1775 K Street, N.W., Washington, DC 20006 (US).			(81) Designated States: AT, AT (European patent), AU, BB, BE (European patent), BF (OAPI patent), BG, BJ (OAPI patent), BR, CF (OAPI patent), CG (OAPI patent), CH, CH (European patent), CM (OAPI patent), DE, DE (European patent), DK, DK (European patent), ES (European patent), FI, FR (European patent), GA (OAPI patent), GB, GB (European patent), HU, IT (European patent), JP, KP, KR, LK, LU, LU (European patent), MC, MG, ML (OAPI patent), MR (OAPI patent), MW, NL, NL (European patent), NO, RO, SD, SE, SE (European patent), SN (OAPI patent), SU, TD (OAPI patent), TG (OAPI patent). Published With international search report. 647732
(54) Title: DNA ENCODING A GROWTH FACTOR SPECIFIC FOR EPITHELIAL CELLS			
(57) Abstract Discoveries are disclosed that show particular aspects or recombinant DNA technology can be used successfully to produce hitherto unknown human keratinocyte growth factor (KGF) protein free of other polypeptides. These proteins can be produced in various functional forms from spontaneously secreting cells or from DNA segments introduced into cells. These forms variously enable biochemical and functional studies of this novel protein as well as production of antibodies. Means are described for determining the level of expression of genes for the KGF protein, for example, by measuring mRNA levels in cells or by measuring antigen secreted in extracellular or body fluids.			

DNA ENCODING A GROWTH FACTOR SPECIFIC FOR EPITHELIAL CELLS

FIELD OF THE INVENTION

The present invention relates to growth factors, particularly to isolation of a polypeptide growth factor similar to a family of factors including known fibroblast growth factors (FGFs). This invention also relates to construction of complementary DNA (cDNA) segments from messenger RNA (mRNA) encoding the novel growth factor. Further, this invention pertains to synthesis of products of such DNA segments by recombinant cells, and to the manufacture and use of certain other novel products enabled by the identification and cloning of DNAs encoding this growth factor.

ABBREVIATIONS USED IN THIS APPLICATION

	aFGF	acidic fibroblast growth factor
	bFGF	basic fibroblast growth factor
	EGF	epidermal growth factor
5	HSAC	heparin-Sepharose affinity chromatography
	kb	kilobases
	kDa	kilodaltons
	KGF	keratinocyte growth factor
10	NaDodSO ₄ /PAGE	Sodium dodecylsulphate (SDS)/ polyacrylamide gel electrophoresis
	RP-HPLC	reversed-phase high performance liquid chromatography
	TGF α	transforming growth factor α

BACKGROUND OF THE INVENTION

Growth factors are important mediators of intercellular communication. These potent molecules are generally released by one cell type and act to influence proliferation of other cell types (see reference I-1 in Experimental Section I, below). Interest in growth factors has been heightened by evidence of their potential involvement in neoplasia (reference II-2 in Experimental Section II, below). The v-sis transforming gene of simian sarcoma virus encodes a protein that is homologous to the B chain of platelet-derived growth factor (I-1, I-2). Moreover, a number of oncogenes are homologues of genes encoding growth factor receptors (I-1). Thus, increased understanding of growth factors and their receptor-mediated signal transduction pathways is likely to provide insights into mechanisms of both normal and malignant cell growth.

One known family of growth factors affecting connective tissue cells includes acidic fibroblast growth factor (aFGF), basic fibroblast growth factor (bFGF), and the related products of the *hst* and *int-2* oncogenes.

Further, it is known that some growth factors, including the following, have heparin-

binding properties: aFGF (I-20, I-21); bFGF (I-19, I-20); granulocyte/macrophage colony stimulating factor (I-1); and interleukin 3 (I-1). Each of these polypeptide factors is produced by stromal cells (I-1, I-2, I-25). Such factors appear to be deposited in the extracellular matrix, or on proteoglycans coating the stromal cell surface (I-1, I-25). It has been postulated that their storage, release and contact with specific target cells are regulated by this interaction (I-25, I-28).

It is widely recognized, however, that the vast majority of human malignancies are derived from epithelial tissues (I-5). Effectors of epithelial cell proliferation derived from mesenchymal tissues have been described (I-1, I-2, I-3), however, their molecular identities and structures have not been elucidated.

In light of this dearth of knowledge about such mesenchymal growth factors affecting epithelial cells, it is apparent that there has been a need for methods and compositions and bioassays which would provide an improved knowledge and analysis of mechanisms of regulation of epithelial cell proliferation, and, ultimately, a need for novel diagnostics and therapies based on the factors involved therein.

This invention contemplates the application of methods of protein isolation and recombinant DNA technologies to fulfill such needs and to develop means for producing protein factors of mesenchymal origin, which appear to be related to epithelial cell proliferation processes and which could not be produced otherwise. This invention also contemplates the application of the molecular mechanisms of these factors related to epithelial cell growth processes.

SUMMARY OF THE INVENTION

The present invention relates to developments of protein isolation and recombinant DNA technologies, which include production of novel growth factor proteins affecting epithelial cells, free of other peptide factors. Novel DNA segments and bioassay methods are also included.

The present invention in particular relates to a novel protein having structural and/or functional characteristics of a known family of growth factors which includes acidic fibroblast growth factor (aFGF), basic fibroblast growth factor (bFGF) and the related products of the *hst* and *int-2* oncogenes. This new member of the FGF polypeptide family retains the heparin-binding properties of the FGFs but has evolved a unique target cell specificity. This growth factor appears to be specific for epithelial cells and is particularly active on keratinocytes. Therefore, this novel factor has been designated "keratinocyte growth factor" (KGF). Notwithstanding its lack of activity on fibroblasts, since it is the sixth known member of the FGF polypeptide family, KGF may also be referred to as FGF-6.

Accordingly, this invention relates, in part, to purified KGF or KGF-like proteins and

methods for preparing these proteins. Such purified factors may be made by cultivation of human cells which naturally secrete these proteins and application of isolation methods according to the practice of this invention. These proteins can be used for biochemical and biological studies leading, for example, to isolation of DNA segments encoding KGF or KGF-like polypeptides.

10 The present invention also relates to such DNA segments which encode KGF or KGF-like proteins. In a principal embodiment, the present invention relates to DNA segments, which encode KGF-related products, consisting of: human cDNA clones 32 or 49, derived from polyadenylated RNA extracted from the human embryonic lung fibroblast cell line M426; recombinants and mutants of these clones; and related DNA segments which can be detected by hybridization to any of the above human DNA segments, which related segments encode KGF-like proteins or portions thereof.

20 In the practice of one embodiment of this invention, the DNA segments of the invention are capable of being expressed in suitable host cells, thereby producing KGF or KGF-like proteins. The invention also relates to mRNAs produced as the result of transcription of the

sense strands of the DNA segments of this invention.

In another embodiment, the invention relates to a recombinant DNA molecule comprising a vector and a DNA of the present invention. These recombinant molecules are exemplified by molecules comprising a KGF cDNA and any of the following vector DNAs: a bacteriophage λ cloning vector (exemplified by λ pCEV9); a DNA sequencing plasmid vector (e.g., a pUC variant); a bacterial gene expression vector (e.g., pKK233-2); or a mammalian gene expression vector (such as pMMT).

In still another embodiment, the invention comprises a cell, preferably a mammalian cell, transformed with a DNA of the invention. Further, the invention comprises cells, including insect cells, yeast cells and bacterial cells such as those of *Escherichia coli* and *B. subtilis*, transformed with DNAs of the invention. According to another embodiment of this aspect of the invention, the transforming DNA is capable of being expressed in the cell, thereby increasing in the cell the amount of KGF or KGF-like protein encoded by this DNA.

The primary KGF translation product predicted from its cDNA sequence contains an N-terminal hydrophobic region which likely serves

as a signal sequence for secretion and which is not present in the mature KGF molecule. In a most preferred embodiment of the gene expression aspect of the invention, the cell transformed by
5 the DNA of the invention secretes the protein encoded by that DNA in the (truncated) form that is secreted by human embryonic lung fibroblast cells.

Still further, this invention
10 contemplates KGF or KGF-like proteins produced by expression of a DNA of the invention, or by translation of an RNA of the invention. Preferably, these proteins will be of the secreted form (i.e., lacking an apparent signal
15 sequence). These protein factors can be used for functional studies, and can be purified for additional structural and functional analyses, such as qualitative and quantitative receptor binding assays.

20 Moreover, the ability to produce large quantities of this novel growth factor by recombinant techniques will allow testing of its clinical applicability in situations where specific stimulation of growth of epithelial
25 cells is of particular importance. Accordingly, this invention includes pharmaceutical compositions comprising KGF or KGF-like polypeptides for use in the treatment of such

conditions, including, for example, healing of wounds due to burns or stimulation of transplanted corneal tissue.

According to this embodiment of the invention, the novel KGF-like proteins will be protein products of "unmodified" DNAs and mRNAs of the invention, or will be modified or genetically engineered protein products. As a result of engineered mutations in the DNA sequences, modified KGF-like proteins will have one or more differences in amino acid sequence from the corresponding naturally occurring "wild-type" proteins. According to one embodiment of this aspect of this invention, the modified KGF-like proteins will include "chimeric" molecules comprising segments of amino acid sequences of KGF and at least one other member of the FGF peptide family.

Ultimately, given results of analogous successful approaches with other peptide factors having similar properties, development of such chimeric KGF-like polypeptides should lead to superior, "second generation" forms of KGF-like peptides for clinical purposes. These modified KGF-like products might be smaller, more stable, more potent, and/or easier or less expensive to produce, for example.

This invention further comprises novel bioassay methods for determining expression in human cells of the mRNAs and proteins produced from the genes related to DNA segments of the invention. According to one such embodiment, DNAs of this invention may be used as probes to determine steady state levels or kinetics of induction of related mRNAs. The availability of the KGF-related cDNA clones makes it possible to determine whether abnormal expression of this growth factor is involved in clinical conditions characterized by excessive epithelial cell growth, including dysplasia and neoplasia (e.g., psoriasis, or malignant or benign epithelial tumors).

This invention also contemplates novel antibodies made against a peptide encoded by a DNA segment of the invention. In this embodiment of the invention the antibodies are monoclonal or polyclonal in origin, and are generated using KGF-related polypeptides from natural, recombinant or synthetic chemistry sources.

The antibodies of this invention bind specifically to KGF or a KGF-like protein which includes the sequence of such peptide, preferably when that protein is in its native (biologically active) conformation. These antibodies can be used for detection or purification of the KGF or

antibodies can be used for detection or
purification of the KGF or KGF-like protein
factors. In a most preferred embodiment of this
aspect of the invention, the antibodies will
5 neutralize the growth promoting activity of KGF,
thereby enabling mechanistic studies and,
ultimately, therapy for clinical conditions
involving excessive levels of KGF.

BRIEF DESCRIPTION OF THE DRAWINGS

Fig. I-1 depicts results of heparin-Sephadex affinity chromatography of conditioned medium from M426 human embryonic fibroblasts showing that greater than 90% of the mitogenic activity for mouse keratinocytes (BALB/MK) eluted with 0.6 M NaCl.

Fig. I-2 illustrates results of further purification of the mitogen from human fibroblasts using HPLC with and adsorptive matrix. Panel (A) shows the profile on reversed-phase (C_4) HPLC of BALB/MK mitogenic activity. Panel (B) presents electrophoretic (NaDodSO₄/PAGE) analysis of selected fractions from the C_4 chromatography shown in panel A, demonstrating that the peak HPLC fractions contained a single band on the silver stained gel. Panel (C) is a bar graph of DNA synthesis in BALB/MK cells triggered by the fractions analyzed in Panel B, showing that the relative mitogenic activity correlated well with the intensity of the protein band across the activity profile.

Fig. I-3 presents an alternative purification step to RP-HPLC, using sieving chromatography with a (TSK G3000SW GlasPac) column run in aqueous solution near physiologic

pH, which resulted in a major peak of . . . togenic activity in the BALB/MK bioassay.

Fig. I-4 illustrates a comparison of BALB/MK DNA synthesis in response to TSK-purified
5 mitogen and other growth factors.

Fig. I-5 shows comparisons of growth of BALB/MK cells in a chemically defined medium in response to different combinations of growth factors.

10 Table I-1 summarizes the results from various purification steps, documenting that sieving chromatography provided a far better recovery of activity than the adsorptive RP-HPLC approach.

15 Table I-2 recapitulates data on the target cell specificities of various growth factors, demonstrating that the newly isolated factor exhibited a strong mitogenic effect on keratinocytes (BALB/MK) and, in striking
20 contrast, had no detectable effects on fibroblasts or human saphenous vein endothelial cells.

Fig. II-1 presents the nucleotide sequence and deduced amino acid sequence of KGF
25 cDNA, as well as identification of RNAs transcribed from the KGF gene. Panel (A) outlines a schematic representation of human KGF cDNA clones. Panel (B) documents the KGF cDNA

nucleotide and predicted amino acid sequences.

(C) Identification of RNA transcripts of KGF genes by Northern blot analysis.

Fig. II-2 illustrates the topological comparison of the FGF family of related molecules, including KGF, with emphasis on the two protein domains that share high homology, the putative signal peptide sequences, and the two conserved cysteine residues.

Fig. II-3 shows (Northern blot) analyses of expression of KGF-related mRNA in selected normal human cell lines and tissues, revealing that a single 2.4 kb transcript was present in RNA from human embryonic lung fibroblasts and from adult skin fibroblasts, while no transcript was detected in the (B5/589) epithelial or (HA83) glial cell lines, or in primary cultures of human saphenous vein endothelial cells.

Table II-1 summarizes a comparison of the effect of heparin on KGF mitogenic activity with effects on other growth factors, showing that thymidine incorporation into DNA by BALB/MK cells in response to KGF was inhibited by heparin, in contrast, to the activities of both aFGF and bFGF which were increased by the same treatment.

DESCRIPTION OF SPECIFIC EMBODIMENTS

This invention relates, in part, to purified KGF or KGF-like proteins and methods for preparing these proteins. A principal embodiment of this aspect of this invention relates to homogeneous KGF characterized by an apparent molecular weight of about 28 kDa based on migration in NaDodSO₄/PAGE, movement as a single peak on reversed-phase high performance liquid chromatography, and a specific activity of at least about 3.4×10^4 units per milligram, and preferably at least about 3.2×10^5 units per milligram, where one unit of activity is defined as that amount which causes half of the maximal possible stimulation of DNA synthesis in certain epithelial (keratinocyte) cells under standard assay conditions outlined below.

To identify novel growth factors specific for epithelial cell types, a clonal BALB/c mouse keratinocyte cell line, designated BALB/MK (I-6) was employed as an indicator cell to detect such factors. These cells are dependent for their growth upon an exogenous source of an epithelial cell mitogen even in medium containing serum (I-6). The development of chemically defined medium for these cells has made it possible to demonstrate that two major

mitogenic pathways are required for BALB/MK proliferation. One involves insulin-like growth factor I (or insulin at high concentration) and the other is satisfied by epidermal growth factor (EGF), transforming growth factor α (TGF α),
5 acidic fibroblast growth factor (aFGF) or basic fibroblast growth factor (bFGF) (I-7).

By using BALB/MK as the prototypical epithelial cell line and NIH/3T3 as its
10 fibroblast counterpart, conditioned media from various human cell lines were assayed for new epithelial cell-specific mitogens. These bioassays of this invention enabled the purification to homogeneity of one such novel
15 growth factor, released by a human embryonic lung fibroblast line, and designated herein as keratinocyte growth factor (KGF).

In brief, the bioassay for KGF-like activity under standard conditions comprises the
20 following steps:

(i) Mouse keratinocytes (BALB/MK cells) are grown in culture to confluency and then maintained for 24-72 hr in serum-free medium;

(ii) Following addition of test samples,
25 stimulation of DNA synthesis is determined by incorporation of ^3H -thymidine into acid-precipitable DNA.

To determine the cell target specificity of a mitogenic growth factor, the DNA synthesis stimulation, expressed as ratio of stimulated synthesis over background incorporation of thymidine in the absence of added test sample, can be compared to analogous stimulation observed in cells other than keratinocytes under the same assay conditions. In such comparisons, KGF mitogenic activity will exhibit marked specificity for the keratinocytes as opposed to fibroblasts (at least about 500-fold greater stimulation) and lesser but significant (at least about 50-fold) greater activity on keratinocytes than on other exemplary epithelial cell types (see Table I-2 for further data, and Materials and Methods in Experimental Section I for details of the standard conditions of the bioassay).

By employing a method of KGF production involving culturing cells and isolating mitogenic activity, which method comprises ultrafiltration, heparin-Sepharose affinity chromatography (HSAC) and adsorptive reversed-phase high performance liquid chromatography (RP-HPLC) or, alternatively, molecular sieving HPLC (TSK-HPLC), according to the present invention, a quantity was isolated sufficient to permit detailed characterization of the physical and biological properties of this molecule.

To summarize, the method for production of KGF from producing cells such as M426 human embryonic fibroblasts (I-8), for example, comprises the following steps:

- 5 (i) Preparation of conditioned media (e.g., 10 liters) using monolayer cultures cycled from serum-containing to serum-free medium and storing the serum-free harvest at -70°C until further use;
- 10 (ii) Concentration by ultrafiltration using membranes having a 10 kDa molecular weight cutoff in several successive steps with intervening dilution in buffer (to facilitate removal of low molecular weight materials), followed by optional
15 storage at -70°C;
- (iii) Affinity chromatography on heparin attached to a polymeric support (e.g., Sepharose) with elution by a gradient of increasing NaCl concentration;
- 20 (iv) Concentration by a factor of at least ten- to twenty-fold with small scale ultrafiltration devices with a 10 kDa molecular weight cutoff (e.g., a Centricc -10
microconcentrator from Amicon) and storage at
25 -70°C.

The next step of the purification process comprises either step (v) or, alternatively, step (vi), as follows:

(v) Reversed-phase HPLC of active fractions (0.6 M NaCl pool) from the previous HSAC step in organic solvent systems;

or,

- 5 (vi) Molecular sieve HPLC (e.g, on a TSK-G3000SW Glas-Pac Column from LKB) in aqueous buffer at near physiological pH (e.g., Tris-HCl, pH 6.8/0.5M NaCl) followed by storage at -70°C.

A preparation made by the TSK step (vi)
10 was almost as pure as one obtained from RP-HPLC, as judged by silver-stained NaDodSO₄/PAGE (data not shown); but the TSK approach provided a far better recovery of activity (Table I-1). Further, the TSK-purified material had a higher
15 specific activity than the RP-HPLC material. KGF prepared by the TSK procedure above stimulated DNA synthesis in epithelial cells at sub-nanomolar concentrations, but failed to induce any thymidine incorporation into DNA of
20 fibroblasts or endothelial cells at comparable or higher concentrations (up to 5 nM). The activity was sensitive to acid, heat and solvents used in the RP-HPLC step. (See Experimental Section I for data on sensitivities and further details of the
25 production method.)

Using standard methodology well known in the art, an unambiguous amino acid sequence was determined for positions 2-13 from the amino

21

terminus of the purified KGF, as follows: Asn-
Asp-Met-Thr-Pro-Glu-Gln-Met-Ala-Thr-Asn-Val (see
Experimental Section I).

The present invention also includes DNA
5 segments encoding KGF and KGF-like polypeptides.
The DNAs of this invention are exemplified by
DNAs referred to herein as: human cDNA clones 32
and 49 derived from polyadenylated RNA extracted
from the human embryonic lung fibroblast cell
10 line M426; recombinants and mutants of these
clones; and related DNA segments which can be
detected by hybridization to these DNA segments.

As described in Experimental Section II,
to search for cDNA clones corresponding to the
15 known portion of the KGF amino acid sequence, two
pools of oligonucleotide probes were generated
based upon all possible nucleotide sequences
encoding the nine-amino acid sequence,
Asn-Asp-Met-Thr-Pro-Glu-Gln-Met-Ala. A cDNA
20 library was constructed in a cDNA cloning vector,
 λ pCEV9, using polyadenylated RNA extracted from
the human embryonic lung fibroblast cell line
M426 which was the initial source of the growth
factor. Screening of the library (9×10^5
25 plaques) with the ^{32}P -labelled oligonucleotides
identified 88 plaques which hybridized to both
probes.

22

of 10 plaque-purified clones that were analyzed, one, designated clone 49, had a cDNA insert of 3.5 kb, while the rest had inserts ranging from 1.8 kb to 2.1 kb. Analysis of the smaller clones revealed several common restriction sites, and sequencing of a representative smaller clone, designated clone 32, along with clone 49, demonstrated that they were overlapping cDNAs (Fig II-1A). Alignment of the two cDNAs established a continuous sequence of 3.85 kb containing the complete KGF coding sequence. The sense strand DNA nucleotide sequence, and the predicted primary protein sequence encoded, are shown for the full-length composite KGF cDNA sequence in Fig. II-1B.

These DNAs, cDNA clones 32 and 49, as well as recombinant forms of these segments comprising the complete KGF coding sequence, are most preferred DNAs of this invention.

From the cDNA sequence, it is apparent that the primary KGF and *hsk* translation products contain hydrophobic N-terminal regions which likely serve as signal sequences, based on similarity to such sequences in a variety of other proteins. Accordingly, this N-terminal domain is not present in the purified mature KGF molecule which is secreted by human embryonic fibroblasts.

Furthermore, KGF shares with all other members of the FGF family two major regions of homology, spanning amino acids 65-156 and 162-189 in the predicted KGF sequence, which are

5 separated by short, nonhomologous series of amino acids of various lengths in the different family members. The sequence of the purified form of KGF contains five cysteine residues, two of which are conserved throughout the family of FGF

10 related proteins. Five pairs of basic residues occur throughout the KGF sequence. This same pattern has been observed in other FGF family members.

It should be obvious to one skilled in

15 the art that, by using the DNAs and RNAs of this invention in hybridization methods (such as Southern blot analyses of genomic human DNAs), especially the most preferred DNAs listed herein above, without undue experimentation, it is

20 possible to screen genomic or cDNA libraries to find other KGF-like DNAs which fall within the scope of this invention. Furthermore, by so using DNAs of this invention, genetic markers associated with the KGF gene, such as restriction

25 fragment length polymorphisms (RFLPs), may be identified and associated with inherited clinical conditions involving this or other nearby genes.

This invention also includes modified forms of KGF DNAs. According to a chief embodiment of this aspect of the invention, such modified DNAs encode KGF-like proteins comprising segments of amino acid sequences of KGF and at least one other member of the FGF peptide family. Thus, for example, since there is no significant N-terminal homology between the secreted form of KGF and analogous positions in other FGF-related proteins, polypeptides with novel structural and functional properties may be created by grafting DNA segments encoding the distinct N-terminal segments of another polypeptide in the FGF family onto a KGF DNA segment in place of its usual NH₂-terminal sequence.

The polypeptide chimeras produced by such modified DNAs are useful for determining whether the KGF NH₂-terminal domain is sufficient to account for its unique target cell specificity. Studies on chimeras should also provide insights into which domains contribute the different effects of heparin on their biologic activities.

Indeed, the utility of this approach has already been confirmed by the successful engineering and expression of a chimeric molecule in which about 40 amino acids from the NH₂-terminus of the secreted form of KGF (beginning

with one amino terminal cys residue of the mature KGF form, numbered 32 in Fig II-1, and ending at KGF residue 78, arg) is linked to about 140 amino acids of the CO₂-terminal core of aFGF (beginning at residue 39, arg, and continuing to the C-terminal end of the aFGF coding sequence. This chimeric product has a target cell preference for keratinocytes, like KGF, but lacks susceptibility to heparin, a characteristic which parallels that of aFGF rather than KGF. This novel KGF-like growth factor may have advantages in clinical applications where administration of an epithelial-specific growth factor is desirable in the presence of heparin, a commonly used anticoagulant. Further details of the construction of this chimeric molecule and the properties of the polypeptide are described in Experimental Section II.

Other DNAs of this invention include the following recombinant DNA molecules comprising a KGF cDNA and any of the following exemplary vector DNAs: a bacteriophage λ cloning vector (λ pCEV9); a DNA sequencing plasmid vector (a pUC variant); a bacterial expression vector (pKK233-2); or a mammalian expression vector (pMTT/neo). Such recombinant DNAs are exemplified by

constructs described in detail in the
Experimental Sections.

Most preferred recombinant molecules
include the following: molecules comprising the
5 coding sequence for the secreted form of KGF and
a bacterial expression vector (e.g., pKK233-2) or
a cDNA encoding the entire primary translation
product (including the NH₂-terminal signal
peptide) and a mammalian expression vector
10 (exemplified by pMMT) capable of expressing
inserted DNAs in mammalian (e.g., NIH/3T3) cells.

Construction of recombinant DNAs
containing KGF DNA and a bacterial expression
vector is described in Experimental Section II.
15 In brief, KGF cDNA was expressed to produce
polypeptide in *E. coli* by placing its coding
sequence under control of the hybrid trk promoter
in the plasmid expression vector pKK233-2 (II-
31).

20 Construction of recombinant DNAs
comprising KGF DNA and a mammalian vector capable
of expressing inserted DNAs in cultured human or
animal cells, can be carried out by standard gene
expression technology using methods well known in
25 the art for expression of such a relatively
simple polypeptide. One specific embodiment of a
recombinant DNA of this aspect of the present

invention, involving the mammalian vector pMMT, is described further below in this section under recombinant cells of this invention.

DNAs and sense strand RNAs of this invention can be employed, in conjunction with protein production methods of this invention, to make large quantities of substantially pure KGF or KGF-like proteins. Substantially pure KGF protein thus produced can be employed, using well-known techniques, in diagnostic assays to determine the presence of receptors for this protein in various body fluids and tissue samples.

Accordingly, this invention also comprises a cell, preferably a bacterial or mammalian cell, transformed with a DNA of the invention, wherein the transforming DNA is capable of being expressed. In a preferred embodiment of this aspect of the invention, the cell transformed by the DNA of the invention produces KGF protein in a fully mitogenic form. Most preferably, these proteins will be of a secreted form (i.e., lacking an apparent signal sequence). These protein factors can be used for functional studies, and can be purified for additional biochemical and functional analyses, such as qualitative and quantitative receptor binding assays.

Recombinant *E. coli* cells have been constructed in a bacterial expression vector, pKK233-2, for production of KGF, as detailed in Experimental Section II. In summary, several
5 recombinant bacterial clones were tested for protein production by the usual small scale methods. All recombinants tested synthesized a protein that was recognized by antibodies raised against an amino-terminal KGF peptide (see
10 below). One recombinant was grown up in a one liter culture which produced recombinant KGF that efficiently stimulated thymidine incorporation into DNA of BALB/MK keratinocyte cells, but was only marginally active on NIH/3T3 fibroblasts.
15 Half-maximal stimulation of the BALB/MK cells in the standard keratinocyte bioassay was achieved with a concentration of between 2 to 5 ng/ml, compared to a concentration of 10 to 15 ng/ml for KGF purified from M426 cells.

20 One liter of bacterial cells yielded approximately 50 μ g of Mono-S purified recombinant KGF. It will be apparent to those skilled in the art of gene expression that this initial yield can be improved substantially
25 without undue experimentation by application of a variety known recombinant DNA technologies.

Recombinant mammalian (NIH/3T3 mouse) cells have also been constructed using the entire

KGF cDNA coding sequence (including the NH₂-terminal signal peptide) and the vector pMMT/neo, which carries mouse metallothionine (MMT) promoter and the selective marker gene for neomycin resistance. The cells are being evaluated for KGF production, particularly for secretion of the mature form (lacking signal peptide) produced by human fibroblasts, using bioassays of the present invention. This same vector and host cell combination has been used successfully to express several other similar recombinant polypeptides, including high levels of Platelet-Derived Growth Factor (PDGF) A and B chains (II-32). Accordingly, it will be recognized by those skilled in the art that high yields of recombinant KGF can be achieved in this manner, using the aforementioned recombinant DNAs and transformed cells of this invention.

Ultimately, large-scale production can be used to enable clinical testing in conditions requiring specific stimulation of epithelial cell growth. Materials and methods for preparing pharmaceutical compositions for administration of polypeptides topically (to skin or to the cornea of the eye, for example) or systemically are well known in the art and can be adapted readily for

administration of KGF and KGF-like peptides without undue experimentation.

This invention also comprises novel antibodies made against a peptide encoded by a DNA segment of the invention. This embodiment of the invention is exemplified by several kinds of antibodies which recognize KGF. These have been prepared using standard methodologies well known in the art of experimental immunology, as outlined in Experimental Section II. These antibodies include: monoclonal antibodies raised in mice against intact, purified protein from human fibroblasts; polyclonal antibodies raised in rabbits against synthetic peptides with sequences based on amino acid sequences predicted from the KGF cDNA sequence [exemplified by a peptide with the sequence of KGF residues 32-45, namely, NDMTPEQMATNVR (using standard one-letter code for amino acid sequences; see Fig. II-1)]; polyclonal antibodies raised in rabbits against both naturally secreted KGF from human fibroblasts and recombinant KGF produced in *E. coli* (see above).

All tested antibodies recognize the recombinant as well as the naturally occurring KGF, either in a solid-phase (ELISA) assay and/or in a Western blot. Some exemplary antibodies, which are preferred antibodies of this invention,

appears to neutralize mitogenic activity of KGF in the BALB/MK bioassay.

Fragments of antibodies of this invention, such as Fab or F(ab)' fragments, which retain antigen binding activity and can be prepared by methods well known in the art, also fall within the scope of the present invention. Further, this invention comprises pharmaceutical compositions of the antibodies of this invention, or active fragments thereof, which can be prepared using materials and methods for preparing pharmaceutical compositions for administration of polypeptides that are well known in the art and can be adapted readily for administration of KGF and KGF-like peptides without undue experimentation.

These antibodies, and active fragments thereof, can be used, for example, for detection of KGF in bioassays or for purification of the protein factors. They may also be used in approaches well known in the art, for isolation of the receptor for KGF, which, as described in Experimental Section II, appears to be distinct from those of all other known growth factors.

Those preferred antibodies, and fragments and pharmaceutical compositions thereof, which neutralize mitogenic activity of KGF for epithelial cells, as indicated by the

BALB/MK assay, for instance, may be used in the treatment of clinical conditions characterized by excessive epithelial cell growth, including dysplasia and neoplasia (e.g., psoriasis, or malignant or benign epithelial tumors).

This invention further comprises novel bioassay methods for detecting the expression of genes related to DNAs of the invention. In some exemplary embodiments, DNAs of this invention were used as probes to determine steady state levels of related mRNAs. Methods for these bioassays of the invention, using KGF DNAs, and standard Northern blotting techniques, are described in detail in Experimental Section II.

One skilled in the art will recognize that, without undue experimentation, such methods may be readily applied to analysis of gene expression for KGF-like proteins, either in isolated cells or various tissues. Such bioassays may be useful, for example, for identification of various classes of tumor cells or genetic defects in the epithelial growth processes.

Without further elaboration, it is believed that one of ordinary skill in the art, using the preceding description, and following the methods of the Experimental Sections below, can utilize the present invention to its fullest

extent. The material disclosed in the
Experimental Sections, unless otherwise
indicated, is disclosed for illustrative purposes
and therefore should not be construed as being
5 limitive in any way of the appended claims.

EXPERIMENTAL SECTION IIDENTIFICATION AND CHARACTERIZATION OF A NOVEL
GROWTH FACTOR SPECIFIC FOR EPITHELIAL CELLS

This section describes experimental work
5 leading to identification of a growth factor
specific for epithelial cells in conditioned
medium of a human embryonic lung fibroblast cell
line. The factor, provisionally termed
keratinocyte growth factor (KGF) because of its
10 predominant activity on this cell type, was
purified to homogeneity by a combination of
ultrafiltration, heparin-Sepharose affinity
chromatography and hydrophobic chromatography on
a C₄ reversed-phase HPLC column, according to
15 methods of this invention. KGF was found to be
both acid and heat labile, and consisted of a
single polypeptide chain with an apparent
molecular weight of approximately 28,000 daltons.
Purified KGF was a potent mitogen for epithelial
20 cells, capable of stimulating DNA synthesis in
quiescent BALB/MK epidermal keratinocytes by more
than 500-fold with activity detectable at 0.1 nM
and maximal at 1.0 nM. Lack of mitogenic
activity on either fibroblasts or endothelial
25 cells indicated that KGF possessed a target cell
specificity distinct from any previously
characterized growth factor. Microsequencing

revealed an amino-terminal sequence containing no significant homology to any known protein. The release of this novel growth factor by human embryonic fibroblasts indicates that KGF plays a role in mesenchymal stimulation of normal epithelial cell proliferation.

METHODS AND MATERIALS

Preparation of Conditioned Media. An early passage of M426 human embryonic fibroblasts (I-8) was plated onto 175 cm² T-flasks and grown to confluence over 10-14 days in Dulbecco's modified Eagle's medium (DMEM; GIBCO) supplemented with 10% calf serum (GIBCO). Once confluent, the monolayers were cycled weekly from serum-containing to serum-free medium, the latter consisting of DMEM alone. The cells were washed twice with 5 ml of phosphate buffered saline prior to addition of 20 ml of DMEM. After 72 hrs, culture fluids were collected and replaced with 35 ml of serum-containing medium. The conditioned medium was stored at -70°C until further use.

Ultrafiltration. Approximately ten liters of conditioned medium were thawed, prefiltered through a 0.50 micron filter (Millipore HAWP 142 50) and concentrated to 200

ml using the Pellicon cassette system (Millipore XX42 00K 60) and a cassette having a 10 kDa molecular weight cutoff (Millipore PTGC 000 05). After concentration, the sample was subjected to
5 two successive rounds of dilution with one liter of 20 mM Tris-HCl, pH 7.5/0.3M NaCl, each followed by another step of ultrafiltration with the Pellicon system. Activity recovered in the retentate was either immediately applied to
10 heparin-Sepharose resin or stored at -70°C.

Heparin-Sepharose Affinity

Chromatography (HSAC). The retentate from ultrafiltration was loaded onto heparin-Sepharose resin (Pharmacia) which had been equilibrated in
15 20 mM Tris-HCl, pH 7.5/0.3 M NaCl. The resin was washed extensively until the optical density had returned to baseline and then subjected to a linear-step gradient of increasing NaCl concentration. After removing aliquots from the
20 fractions for the thymidine incorporation bioassay, selected fractions were concentrated ten- to twenty-fold with a Centricon-10 microconcentrator (Amicon) and stored at -70°C.

Reversed-Phase HPLC (RP-HPLC). Active
25 fractions (0.6 M NaCl pool) from the HSAC were thawed, pooled and further concentrated with the Centricon-10 to a final volume of ≤ 200 μ l. The sample was loaded onto a Vydac C₁₈ HPLC column (The

Separations Group, Hesperia, CA) which had been equilibrated in 0.1% trifluoroacetic acid (TFA, Fluka)/20% acetonitrile (Baker, HPLC grade) and eluted with a linear gradient of increasing acetonitrile. Aliquots for the bioassay were immediately diluted in a 10-fold excess of 50 μ g/ml BSA (Fraction V, Sigma)/20 mM Tris-HCl, pH 7.5. The remainder of the sample was dried in a Speed-Vac (Savant) in preparation for structural analysis.

Molecular Sieve HPLC. Approximately 50 μ l of the twice concentrated heparin-Sepharose fractions were loaded onto a TSK-G3000SW Glas-Pac Column (LKB) which had been equilibrated in 20 mM Tris-HCl, pH 6.8/0.5M NaCl. The sample was eluted in this buffer at a flow rate of 0.4 ml/min. After removing aliquots for the bioassay, the fractions were stored at -70°C.

NaDodSO₄-Polyacrylamide Gel Electrophoresis (NaDodSO₄/PAGE). Polyacrylamide gels were prepared with NaDodSO₄ according to the procedure of Laemmli (I-9). Samples were boiled for 3 min in the presence of 2.5% 2-mercaptoethanol (vol/vol). The gels were fixed and stained with silver (I-10) using the reagents and protocol from BioRad. Molecular weight markers were from Pharmacia.

DNA Synthesis Stimulation. Ninety-six well microtiter plates (Falcon No. 3596) were precoated with human fibronectin (Collaborative Research) at $1 \mu\text{g}/\text{cm}^2$ prior to seeding with
5 BALB/MK cells. Once confluent, the cells were maintained for 24-72 hr in serum-free medium containing $5 \mu\text{g}/\text{ml}$ transferrin (Collaborative Research) and 30 nM Na_2SeO_3 (Baker).
Incorporation of ^3H -thymidine ($5 \mu\text{Ci}/\text{ml}$ final
10 concentration, NEN) into DNA was measured during a 6 hr period beginning at 16 hrs following addition of samples. The assay was terminated by washing the cells once with ice cold phosphate-buffered saline and twice with 5% trichloroacetic
15 acid. The precipitate was redissolved in 0.25 M NaOH , transferred into liquid scintillation fluid (Biofluor, NEN) and counted.

Stimulation of DNA synthesis was monitored as described above for BALB/MK cells on
20 a variety of other cell lines. NIH/3T3 fibroblasts (I-11) were available from the National Institutes of Health, while CCL208 Rhesus monkey bronchial epithelial cells (I-12) were obtained from the American Type Culture
25 Collection. The B5/589 human mammary epithelial cell line, prepared as described in (I-13), was obtained from Martha Stampfer (University of California, Berkeley). The mammary cells were

grown in RPMI 1640 supplemented with 10% fetal calf serum and 4 ng/ml EGF. When maintained in serum-free conditions, the basal medium was DMEM. Primary cultures of human saphenous vein
5 endothelial cells were prepared and maintained as described elsewhere (I-14). Epidermal growth factor and insulin were from Collaborative Research. Acidic FGF and bFGF were obtained from California Biotechnology, Inc. Recombinant TGF α
10 was obtained from Genentech, Inc. Media and serum were either from GIBCO, Biofluids, Inc. or the NIH media unit.

Proliferation Assay. Thirty-five mm culture dishes were precoated sequentially with
15 poly-D-lysine (20 $\mu\text{g}/\text{cm}^2$) (Sigma) and human fibronectin, and then seeded with approximately 2.5×10^4 BALB/MK cells. The basic medium was a 1:1 mixture of Eagle's low Ca^{2+} minimal essential medium and Ham's F-12 medium, supplemented with 5
20 $\mu\text{g}/\text{ml}$ transferrin, 30 nM Na_2SeO_3 and 0.2 mM ethanolamine (Sigma). Medium was changed every 2 or 3 days. After 10 days, the cells were fixed in formalin (Fisher Scientific Co.) and stained with Giemsa (Fisher Scientific Co.).

25 Protein microsequencing. Approximately 4 μg (-150 pmol) of protein from the active fractions of the C_4 column were redissolved in 50% TFA and loaded onto an Applied Biosystems gas-

phase protein sequenator. Twenty rounds of Edman degradation were carried out and identifications of amino acid derivatives were made with an automated on-line HPLC (Model 120A, Applied Biosystems).

RESULTS

Growth Factor Detection and Isolation.

Preliminary screening of conditioned media from various cell lines indicated that media from some fibroblast lines contained mitogenic activities detectable on both BALB/MK and NIH/3T3 cells. Whereas boiling destroyed the activity on BALB/MK, mitogenic activity on NIH/3T3 remained intact. Based on the known heat stability of EGF (I-15) and TGF α (I-16), it was reasoned that the BALB/MK mitogenic activity might be due to an agent different from these known epithelial growth factors.

M426, a human embryonic lung fibroblast line, was selected as the most productive source of this activity for purification of the putative growth factor(s). Ultrafiltration with the Pellicon system provided a convenient way of reducing the sample volume to a suitable level for subsequent chromatography. Various combinations of sieving, ion exchange and

isoelectric focusing chromatography were tried during the development of a purification scheme, but all resulted in unacceptably low yields. On the other hand, heparin-Sephacrose affinity chromatography (HSAC), which has been employed in the purification of other growth factors (I-17-I-22), proved to be useful as an early purification step in the present invention. While estimates of recovered specific activity were uncertain at this stage because of the likely presence of other factors, the apparent yield of activity was 50-70% with a corresponding enrichment of approximately 1000 fold.

Heparin Sepharose affinity chromatography of conditioned medium from M426 human embryonic fibroblasts is shown in Fig. I-1. Heparin-Sephacrose affinity chromatography of conditioned medium from M426 human embryonic fibroblasts. Approximately 150 ml of ultrafiltration retentate derived from liters of M426 conditioned medium were loaded onto a heparin-Sephacrose column (6 ml bed volume) in 1 hr. After washing the column with 150 ml of the equilibration buffer, 20 mM Tris-HCl, pH 7.5/0.3M NaCl, the retained protein (<5% of the total protein in the retentate) was eluted with a modified linear gradient of increasing NaCl concentration. Fraction size was 3.8 ml and flow rate during gradient elution was 108 ml/hr. Two μ l of the indicated fractions were transferred to the microtiter wells containing a final volume of 0.2 ml for assay of ^{3} H-thymidine incorporation in BALB/MK cells as described in the Methods.

As shown in Fig. I-1, greater than 90% of the BALB/MK mitogenic activity eluted from the HSAC column with 0.6M NaCl. This peak of activity was not associated with any activity on NIH/3T3 cells (data not shown). A much smaller peak of BALB/MK mitogenic activity consistently emerged with 0.8 - 1.2M NaCl.

Due to the reproducibility of the HSAC pattern, active fractions could be identified presumptively on the basis of the gradient and optical density profile. Prompt concentration of 10-20 fold with the Centricon-10 was found to be essential for stability, which could be maintained subsequently at -70°C for several months.


Final purification was achieved by RP-HPLC with a C₄ Vydac column, a preparative method suitable for amino acid sequence analysis. While the yield of activity from the C₄ step was usually only a few percent, this loss could be attributed to the solvents employed. In other experiments, exposure to 0.1% TFA/50% acetonitrile for 1 hr at room temperature reduced the mitogenic activity of the preparation by 98%. Nonetheless, as shown in Fig. I-2, a single peak of BALB/MK stimulatory activity was obtained, coinciding with a distinct peak in the optical density profile.

In this representative experiment active fractions eluted from heparin-Sepharose with 0-6M NaCl were processed with the Centricon -10 and loaded directly onto a C₄ Vydac column (4.6 x 250 mm) which had been equilibrated in 0.1% trifluoroacetic acid/20% acetonitrile (ACN). After washing the column with 4 ml of equilibration buffer, the sample was eluted with a modified linear gradient on increasing % ACN. Fraction size was 0.2 ml and flow rate was 0.5 ml/min. Aliquots for the assay of ³H-thymidine incorporation in BALB/MK cells were promptly diluted 10-fold with 50 µg/ml bovine serum albumin/20 mM Tris-HCl, pH 7.5, and tested at a final dilution of 200-fold.

NaDodSO₄/PAGE analysis of selected fractions from the C₄ chromatography shown in panel A is presented in panel B. (B) Half of each fraction was dried, redissolved in NaDodSO₄/2-mercaptoethanol, heat denatured and electrophoresed in a 14% polyacrylamide gel which was

subsequently stained with silver. The position of each molecular weight marker (mass in kDa) is indicated by an arrow. In panel C we show the DNA synthesis in BALB/MK cells triffered by the fractions analyzed in panel B. Activity is expressed as the fold stimulation over background which was 100 cpm.

An alternative purification step to the HPLC technique described above using approximately 50 μ l of a Centricon-processed, 0.6M NaCl pool from HSAC were loaded onto a LKB GlasPac TSK G3000SW column (8 x 300 mm), previously equilibrated in 20 mM Tris-HCl, pH 6.8/0.5M NaCl, and eluted as 0.2 ml fractions at a flow rate of 0.4 ml/min. Aliquots of 2 μ l were transferred to microtiter wells containing a final volume of 0.2 ml for assay of ^{3} H-thymidine incorporation in BALB/MK cells. The elution positions of molecular weight markers (mass in kDa) were as indicated by the arrows. This resulted in a major peak of activity in the BALB/MK bioassay (Fig. I-3). This preparation was almost as pure as the one obtained from RP-HPLC as judged by silver-stained NaDodSO₄/PAGE (data not shown) but provided a far better recovery of activity (Table I-1). The TSK-



purified material was used routinely for biological studies as it had a higher specific activity.

In both types of purified preparations (i.e., purified by HPLC or molecular sieving), the profile of mitogenic activity was associated with a distinct band on NaDodSO₄/PAGE which appeared to be indistinguishable in the two preparations.

Physical and Biological Characterization of the Growth Factor. The purified factor had an estimated molecular weight of about 28 kDa based on NaDodSO₄/PAGE under reducing (Fig. I-2) and non-reducing conditions (data not shown). This value was in good agreement with its elution position on two different sizing columns run in solvents expected to maintain native conformation (TSK-G3000-SW, Fig. I-3, and superose-12, data not shown). From these data, the mitogen appears to consist of a single polypeptide chain with a molecular weight of 25-30 kDa.

The heat and acid lability of the mitogenic activity were demonstrated using the BALB/MK mitogenesis bioassay. While activity was unaffected by a 10 min incubation at 50°C, it was reduced by 68% after 10 min at 60°C and was undetectable after 3 min at 100°C. Exposure to 0.5M acetic acid for 60 min at room temperature

resulted in a decline in activity to 14% of the control. In comparison, the mitogenic activity of the known growth factor, EGF, was not diminished by any of these treatments.

5 A comparison of BALB/MK DNA synthesis in response to TSK-purified mitogen and other growth factors. Incorporation of ³H-thymidine into trichloroacetic acid-insoluble DNA, expressed as fold stimulation over background, was measured as a function of the concentration of the indicated growth factors. Background values with no
10 sample added were 150 cpm. The results represent mean values of two independent experiments. Replicates in each experiment were within 10% of mean values. TSK-purified mitogen, • — •; EGF, ▲ — ▲; aFGF, • — •; bFGF, ° — °.

15 The dose response curve for the purified growth factor depicted in Fig. I-4 illustrates that as little as 0.1 nM led to a detectable stimulation of DNA synthesis. Thus, the activity range was comparable to that of the other growth factors analyzed to date. A linear
20 relationship was observed in the concentration range 0.1 - 1.0 nM with maximal stimulation of 600 fold observed at 1.0 nM. The novel factor consistently induced a higher level of maximal thymidine incorporation than EGF, aFGF, or bFGF in the BALB/MK keratinocytes (Fig. I-4).

25 The distinctive target cell specificity of this factor was demonstrated by comparing its activities on a variety of cell types with those of other growth factors known to possess epithelial cell mitogenic activity. As shown in Table I-2, the newly isolated factor exhibited a
30 strong mitogenic effect on BALB/MK but also induced demonstrable incorporation of thymidine into DNA of the other epithelial cells tested. In striking contrast, the factor had no detectable mitogenic effects on mouse (or human, data not shown) fibroblasts or human saphenous vein



endothelial cells.

By comparison, none of the other known growth factors appeared to preferentially stimulate keratinocytes. TGF α and EGF showed potent activity on fibroblasts, while the FGFs were mitogenic for endothelial cells as well as fibroblasts (Table I-2). Because of its specificity of epithelial cells and the sensitivity of keratinocytes in particular, the novel mitogen was provisionally designated as keratinocyte growth factor (KGF).

To establish that KGF not only would stimulate DNA synthesis but would also support sustained cell growth, the ability of BALB/MK cells to grow in a fully-defined, serum-free medium supplemented with this growth factor was assessed. Cultures were plated at a density of 2.5×10^4 cells per dish on 35 mm Petri dishes precoated with poly-D-lysine/fibronectin in a 1:1 mixture of Eagle's minimal essential medium and Ham's F12 medium supplemented with transferrin, Na_2SeO_3 , ethanolamine and the growth factors indicated below. After 10 days, the plates were fixed and stained with Giemsa. Key: a) no growth factor; b) EGF alone; c) insulin alone; d) KGF alone; e) EGF + insulin. Final concentrations of the growth factors were as follows: EGF, 20 ng/ml; insulin, 10 $\mu\text{g}/\text{ml}$; and KGF, 40 ng/ml. As shown in Fig. I-5, KGF served as an excellent substitute for EGF but not insulin (or insulin-like growth factor I) in this chemically defined medium. Thus, KGF appears to act through the major signalling pathway shared by EGF, aFGF and bFGF for proliferation of BALB/MK cells.

Microsequencing Reveals a Unique N-terminal Amino Acid Sequence of KGF. To further characterize the growth factor, approximately 150 pmol of C_4 -purified material were subjected to amino acid sequence analysis. A single sequence -----

was detected with unambiguous assignments made for cycles 2-13, as follows: X-Asn-Asp-Met-Thr-Pro-Glu-Gln-Met-Ala-Thr-Asn-Val. High background noise precluded an assignment for the first
5 position which is, therefore, indicated by an X.

A computer search using the FASTP program (I-24) revealed that the N-terminal amino acid sequence of KGF showed no significant homology to any protein in the National
10 Biomedical Research Foundation data bank, thus supporting the novelty of this epithelial growth factor.

DISCUSSION

The studies described in this
15 Experimental Section identified a human growth factor which has a unique specificity for epithelial cells. By employing ultrafiltration, HSAC and RP-HPLC or TSK sieving chromatography according to the present invention, a quantity
20 sufficient to permit detailed characterization of the physical and biological properties of this molecule was isolated.

A single silver-stained band corresponding to a molecular weight of about
25 28,000 daltons was detected in the active fractions from RP-HPLC, and the intensity of the

band was proportional to the level of mitogenic activity in these fractions. A band indistinguishable from that obtained by RP-HPLC was seen in the active fractions from TSK chromatography. The purified protein stimulated DNA synthesis in epithelial cells at sub-nanomolar concentrations, but failed to induce any thymidine incorporation in fibroblasts or endothelial cells at comparable or higher concentrations (up to 5 nM). This distinctive target cell specificity combined with the single novel N-terminal amino acid sequence determined from the purified molecule lead to the conclusion that KGF represents a new growth factor.

In a chemically defined medium the purified factor was able to complement the insulin-like growth factor I/insulin growth requirement of BALB/MK cells and therefore must act through a signal transduction pathway shared with EGF, TGF α and the FGFs. Moreover, the new factor was more potent than any of the known epithelial cell mitogens in stimulating thymidine incorporation in BALB/MK cells. Preliminary evidence indicates that this factor is also capable of supporting proliferation of secondary cultures of human keratinocytes (data not shown).

Handling and storage of KGF were problematical during its purification. Besides

its inherent lability to acid and heat, it was unstable to lyophilization or dialysis. After HSAC, complete loss of activity occurred within 24 hr despite the use of carrier proteins, heparin, protease inhibitors, siliconized tubes or storage at either 4° or -20°C. Only concentrating the sample at this stage could preserve its activity.

Furthermore, in order to transfer the dried, purified factor it was necessary to utilize either strong acid or detergent, consistent with an adsorptive tendency or insolubility. Thus, for preservation of activity, the purified factor was maintained in solution at high concentrations at -70°C where it remained stable for several months.

The ability of KGF to bind heparin may signify a fundamental property of this factor that has a bearing on its function *in vivo*. Growth factors with heparin-binding properties include aFGF (I-20--I-22) bFGF (I-19, I-22) granulocyte/macrophage colony stimulating factor and interleukin 3. (I-25) Each of these is produced by stromal cells (I-25--I-27). Such factors appear to be deposited in the extracellular matrix, or on proteoglycans coating the stromal cell surface (I-25, I-28). It has been postulated that their storage, release and

contact with specific target cells are regulated by this interaction (I-25, I-28). While mesenchymal-derived effectors of epithelial cell proliferation have also been described (I-29--I-31), their identities have not been elucidated. Its heparin-binding properties, release by human embryonic fibroblast stromal cells, and epithelial cell tropism provide KGF with all of the properties expected of such a paracrine mediator of normal epithelial cell growth.

The partial amino acid sequence determined for this new growth factor has enabled molecular cloning of its coding sequence and determination of its structural relationship to known families of growth factors, as described in Experimental Section II, below.

REFERENCES FOR EXPERIMENTAL SECTION I

- I-1. James, R. and Bradshaw, R.A. (1984) *Ann. Rev. Biochem.* 53, 259-292.
- I-2. Doolittle, R.F., Hunkapiller, M.W., Hood, L.E., Devare, S.G., Robbins, K.C., Aaronson, S.A. and Antoniades, M.N. (1983) *Science* 221, 275-277.
- I-3. Waterfield, M.D., Scrace, G.J., Whittle, N., Strooband, P., Johnson, A., Wasteton, A., Westermark, B., Heldin,

- C.-H., Huang, J.S. and Deuel, T.F.
(1983) *Nature* 304, 35-39.
- I-4. Hunter, T. and Cooper, J.A. (1985) *Annu. Rev. Biochem.* 54, 897-930.
- 5 I-5. Wright, N. and Allison, M. (1984) *The Biology of Epithelial Cell Populations* (Oxford University Press, New York) Vol. 1, pp. 3-5.
- I-6. Weissman, B.E. and Aaronson, S.A. (1983)
10 *Cell* 32, 599-606.
- I-7. Falco, J.P., Taylor, W.G., DiFiore, P.P., Weissman, B.E., and Aaronson, S.A. (1988) *Oncogene* 2, 573-578.
- I-8. Aaronson, S.A. and Todaro, G.J. (1968)
15 *Virology* 36, 254-261.
- I-9. Laemmli, U.K. (1970) *Nature* 227, 680-685.
- I-10. Merril, C.R., Goldman, D., Sedman, S.A. and Ebert, M.H. (1981) *Science* 211, 1437-1438.
- 20 I-11. Jainchill, J.L., Aaronson, S.A. and Todaro, G.J. (1969) *J. Virol.* 4, 549-553.
- I-12. Caputo, J.L., Hay, R.J. and Williams, C.D. (1979) *In Vitro* 15, 222-223.
- I-13. Stampfer, M.R. and Bartley, J.C. (1985)
25 *Proc. Natl. Acad. Sci. USA* 82, 2394-2398.

- I-14. Sharefkin, J.B., Fairchild, K.D., Albus, R.A., Cruess, D.F. and Rich, N.M. (1986) *J. Surgical Res.* 41, 463-472.
- 5 I-15. Cohen, S. (1962) *J. Biol. Chem.* 237, 1555-1562.
- I-16. DeLarco, J.E. and Todaro, G.J. (1978) *Proc. Natl. Acad. Sci. USA* 75, 4001-4005.
- I-17. Raines, E.W. and Ross, R. (1982) *J. Biol. Chem.* 257, 5154-5160.
- 10 I-18. Shing, Y., Folkman, J., Sullivan, R., Butterfield, C., Murray, J. and Klagsburn, M. (1984) *Science* 223, 1296-1299.
- 15 I-19. Gospodarowicz, D., Cheng, J., Lui, G.-M., Baird, A. and Bohlen, P. (1984) *Proc. Natl. Acad. Sci. USA* 81, 6963-6967.
- I-20. Maciag, T., Mehlman, T., Friesel, R. and Schreiber, A.B. (1984) *Science* 225, 932-935.
- 20 I-21. Conn, G. and Hatcher, V.B. (1984) *Biochem. Biophys. Res. Comm.* 124, 262-268.
- I-22. Lobb, R.R. and Fett, J.W. (1984) *Biochemistry* 23, 6295-6299.
- 25 I-23. Bradford, M. (1976) *Anal. Biochem.* 72, 248-254.

- I-24. Lipman, D.J. and Pearson, R.W. (1985)
Science 227, 1435-1441.
- I-25. Roberts, R., Gallagher, J., Spooncer,
E., Allen, T.D., Bloomfield, F. and
5 Dexter, T.M. (1988) *Nature* 332, 376-378.
- I-26. Libermann, T.A., Friesel, R., Jaye, M.,
Lyall, R.M., Westermarck, B., Drohen, W.,
Schmidt, A., Maciag, T. and
Schlessinger, J. (1987) *EMBO J.*, 6, 1627-
10 1632.
- I-27. Shipley, G.D., Sternfeld, M.D., Coffey,
R.J. and Pittelkow, M.R. (1988) *J. Cell*
Biochem. Supp 12A, 125, abstr. C420.
- I-28. Vlodavsky, I., Folkman, J., Sullivan,
15 R., Fridman, R., Ishai-Michaeli, R.,
Sasse, J. and Klagsburn, M. (1987) *Proc.*
Natl. Acad. Sci. USA 84, 2292-2296.
- I-29. Gilchrest, B.A., Karassik, R.L.,
Wilkins, L.M., Vrabel, M.A. and Maciag,
20 T. (1983) *J. Cell Physiol.* 117, 2325-240.
- I-30. Chan, K.Y. and Haschke, R.H. (1983) *Exp.*
Eye Res. 36, 231-246.
- I-31. Stiles, A.D., Smith, B.T. and Post, M.
(1986) *Exp. Lung Res.* 11, 165-177.

EXPERIMENTAL SECTION II

CDNA SEQUENCE OF
A NOVEL EPITHELIAL CELL SPECIFIC GROWTH FACTOR
DEFINES A NEW MEMBER OF THE FGF FAMILY

5 Work in the previous Experimental
Section I identified and purified a novel
heparin-binding growth factor, designated
keratinocyte growth factor (KGF), which is
particularly active on keratinocytes and appears
10 to be specific for epithelial cells. This second
Experimental Section describes the isolation and
characterization of cDNA clones encoding KGF,
using synthetic oligonucleotides, based upon the
experimentally determined NH₂-terminal amino acid
15 sequence, as hybridization probes. Nucleotide
sequence analysis identified a 582-bp open
reading frame which would code for a 194-amino
acid polypeptide that is between 41% and 33%
identical to the heparin-binding acidic and basic
20 fibroblast growth factors (FGFs), and the related
products of the *hst* and *int-2* oncogenes. The KGF
gene RNA transcript is expressed in normal
fibroblasts of both embryonic and adult origin,
but not in epithelial, endothelial or glial
25 cells. Thus, KGF appears to be normally
expressed by the mesenchyme, indicating a role in
the regulation of epithelial cell proliferation.

MATERIALS AND METHODS

Isolation of cDNA clones.

The purification and N-terminal sequencing of KGF has been previously described (see Experimental Section I, above and II-3). Pools (50 pmole) of deoxyoligonucleotides described under Results were 5' end-labelled using 83 pmole of γ - ^{32}P -ATP (3000 Ci/mmole, Amersham) and 10 units of T4 polynucleotide kinase. The recombinant phage carrying cDNA clones were replica plated onto nitrocellulose filters and hybridized with ^{32}P -labelled deoxyoligonucleotides in 20% formamide, 10% dextran sulphate, 10 mM Tris-HCl (pH 7.5), 8 x SSC, 5x Denhardt's and 50 $\mu\text{g}/\text{ml}$ denatured salmon sperm DNA, overnight at 42°C. Filters were washed in 0.5 x SSC, 0.1% SDS at 50°C and exposed to Kodak X-omat AR film.

DNA sequencing. The nucleotide sequence of the KGF cDNA was determined by the dideoxy chain termination method (II-26), of overlapping restriction fragments, subcloned into pUC vectors (II-27)

Construction of a bacterial expression vector for KGF cDNA. KGF cDNA encoding the mature, secreted form of the polypeptide was placed under control of the hybrid trk promoter

in the plasmid expression vector pKK233-2 (II-31), as follows. To accomplish this, a specific length of KGF cDNA that contained the information to code for the mature KGF molecule (i.e.,
5 without its signal peptide) was amplified using the polymerase chain reaction (PCR) technique (II-32). The fragment was directionally inserted between two sites in the vector, namely the *Nco*I site, made blunt ended by *S*1 nuclease digestion,
10 and the *Hind*III site, using standard recombinant DNA methodology. The ends of the KGF cDNA produced by the PCR method were as follows: the 5' end was blunt and began with an ATG codon, followed by the codon TGC for cys residue, number
15 33, which is the amino terminal residue of the mature form of KGF (see Fig. II-1), and then the entire KGF coding sequence. The stop codon, TAA, and the four bases immediately following, TTGC, were also included on the 3' end of the cDNA.
20 The primer used in the PCR method to direct DNA synthesis to the desired position on the 3' end of the cDNA included a *Hind*III site for insertion of the amplified cDNA into the vector DNA.

Production of antibodies against KGF and
25 KGF-related peptides. Monoclonal antibodies were raised in mice against intact, purified protein from human fibroblasts using 5 or more

subcutaneous injections. Test bleeds were screened with a solid-phase (ELISA) assay using highly purified KGF from human epithelial cells as antigen. Hybridomas were prepared by routine methods and supernatants were screened with the ELISA assay to detect KGF-reactive antibodies. Positive clones were serially subcloned by the usual methods, and selected subclones were grown as ascites tumors in mice for production of large amounts of antibodies. Antibodies were purified from ascites fluids employing standard techniques (e.g., hydroxyapatite or immunoaffinity resins).

Polyclonal antibodies against a synthetic peptide were raised in rabbits by standard methods, as follows. The peptides were made by solid phase technology and coupled to thyroglobulin by reaction with glutaraldehyde. Serial subcutaneous injections were made and test bleeds were screened by ELISA as well as other techniques, including Western blot analysis and mitogenesis bioassay. IgG immunoglobulins were isolated by affinity chromatography using immobilized protein G.

Polyclonal antibodies were raised in rabbits against both naturally secreted KGF from human fibroblasts and recombinant KGF produced in *E. coli* (see next section), using the following protocol:

57

- i) Initial injection and first boost were administered in the inguinal lymph nodes;
- ii) subsequent boosts were made intramuscularly.

5

Screening of test bleeds included ELISA as well as Western blot analysis and mitogenesis bioassay, and IgG was purified as for antibodies against synthetic peptides, above.

RESULTS

Isolation of cDNA clones encoding the novel growth factor. To search for cDNA clones corresponding to the KGF coding sequence, two
5 pools of oligonucleotides with lengths of 26 bases were generated based upon a nine-amino acid sequence, Asn-Asp-Met-Thr-Pro-Glu-Gln-Met-Ala, as determined by microsequencing of purified KGF
(see Experimental Section I, above and reference
10 II-3). One oligonucleotide pool contained a mixture of all 256 possible coding sequences for the nine amino acids, while the other contained inosine residues at the degenerate third position of the codons for Thr and Pro.

15 This latter design reduced the number of possible coding sequences in the pool to 16. Inosine in a tRNA anticodon can form hydrogen bonds with A, C or U (II-4), and oligonucleotides that contain deoxyinosine have been shown to
20 hybridize efficiently with the corresponding cDNA (II-5).

A cDNA library was constructed in a cDNA cloning vector, pCEV9 (II-6) using polyadenylated RNA extracted from the human
25 embryonic lung fibroblast cell line M426 (II-7), the initial source of the growth factor. Screening of the library (9×10^5 plaques) with

the ^{32}P -labelled 26-mer oligonucleotides identified 88 plaques which hybridized to both pools of oligonucleotide probes.

Characterization and sequencing of selected

5 cDNA clones. Of 10 plaque-purified clones that were analyzed, one, designated clone 49, had a cDNA insert of 3.5 kb, while the rest had inserts ranging from 1.8 kb to 2.1 kb.


10 Analysis of the smaller clones revealed several common restriction sites. Sequencing of a representative smaller clone, designated clone 32, along with clone 49, demonstrated that they were overlapping cDNAs as shown in Fig. II-1A. Overlapping pCEV9 clones 32 and 49, used in
15 sequence determination, are shown above a diagram of the complete structure in which untranslated regions are depicted by a line and the coding sequence is boxed. The hatched region denotes sequences of the signal peptide and the open region of the mature protein. Selected
20 restriction sites are indicated. Whereas clone 49 was primed from the poly(A) tail of the message, clone 32 arose during the construction of the library by hybridization of the oligo (dT) primer to an A-rich sequence in the 3' noncoding region of the KGF mRNA.

Description of the sequence encoding the

25 KGF polypeptide. Alignment of the two cDNAs (clones 32 and 49) established a continuous sequence of 3.85 kb containing the complete KGF coding sequence. The KGF cDNA nucleotide and predicted amino acid sequences are shown in Fig. II-1B. Nucleotides are numbered on the right; amino acids are
30 numbered throughout. The N-terminal peptide sequence derived from purified KGF is underlined. the hydrophobic N-terminal domain is italicized. the potential asparagine-linked glycosylation site is overlined. The variant polyadenylation signals, AATTAA and AATACA, close to the 3'

59a

end of the RNA, are boxed. An ATG likely to be an
initiation codon was located at nucleotide position 446,
establishing a 582-base pair open reading frame that ended
5 at a TAA termination codon at position 1030. This open
reading frame



would encode a 194-amino acid polypeptide with a calculated molecular weight of 22,512 daltons.

The sequence flanking the ATG codon did not conform to the proposed GCC(G/A)CCATGG
5 consensus for optimal initiation by eukaryotic ribosomes (II-8), however, there was an A three nucleotides upstream of the ATG codon. An A at this position is the most highly conserved nucleotide in the consensus. This ATG codon was
10 preceded 85 nucleotides upstream by a TGA stop codon in the same reading frame.

A 19-amino acid sequence that was homologous to the experimentally determined NH₂-terminus of purified KGF began 32 amino acids
15 downstream of the proposed initiation codon. There was complete agreement between the predicted and experimentally determined amino acid sequences, where unambiguous assignments could be made.

20 To search for homology between KGF and any known protein, a computer search of the National Biomedical Research Foundation data base using the FASTP program of Lipman and Pearson was conducted (II-9). By this approach, a striking
25 degree of relatedness between the predicted primary structure of KGF and those of acidic and

basic FGF, as well as the related *hst* and *int-2*-encoded proteins was revealed.

Expression of mRNA transcripts of the KGF gene in human cells. Identification of KGF mRNAs by Northern blot analysis. Lanes a and c contained, poly(A)-selected M426 RNA; lane d and b contained, total cellular M426 RNA. Filters were hybridized with a ³²P-labeled 695 bp *Bam*HI/*Bcl*II fragment from clone 32 (Probe A, Fig. II-1A), lanes a and b. In preliminary attempts to examine expression of KGF mRNA in human cells, a probe spanning the majority of the KGF coding sequence (Probe A, Figure II-1A) detected a single 2.4 kb transcript by Northern blot analysis of total M426 RNA (Figure II-1C). This was considerably shorter than the length of the composite cDNA sequence, 3.85 kb.

However, on screening poly(A)-selected M426 RNA, an additional transcript of approximately 5 kb was detected. Furthermore, a probe derived from the untranslated region of clone 49, 3' to the end of clone 32 (Probe B, Figure II-1A), hybridized only to the larger message (Figure II-1C). Thus, it appears that the KGF gene is transcribed as to alternate RNAs. Two other members of the FGF gene family, bFGF (II-29) and *int-2* (II-30), also express multiple RNAs, the significance of which remains to be determined.

To investigate the normal functional role of KGF, the expression of its transcript in a variety of human cell lines and tissues was examined. Northern blot analysis of KGF mRNA in normal human cell lines and tissues, and comparison with mRNA expression of other growth factors with known activity on epithelial cells is presented in Fig. II-3. As shown in Figure II-3, the _____

predominant 2.4 kb KGF transcript was detected in each of several stromal fibroblast lines derived from epithelial tissues of embryonic, neonatal and adult sources, but not from epithelial cell lines of normal origin. The transcript was also detected in RNA extracted from normal adult kidneys and organs of the gastrointestinal tract, but not from lung or brain. The striking specificity of KGF RNA expression in stromal cells from epithelial tissues indicated that this factor plays a normal role in mesenchymal stimulation of epithelial cell growth.

For comparison, the mRNAs of other growth factors with known activity on epithelial cells were also analyzed in the same tissues as listed above. Among the epithelial and stromal cell lines analyzed, there was no consistent pattern of expression of aFGF or bFGF transcripts (Fig. II-3). The EGF transcript was not expressed in any of the same cell lines, and was only observed in kidney, among the various tissues. Finally, the TGF α message was not detected in any of the stromal fibroblast lines and was expressed at varying levels in each of the epithelial cell lines. It was also detected at low levels in kidney among the tissues examined (Fig. II-3).

Inhibition of KGF mitogenic activity by heparin. Heparin has been shown to substantially increase the mitogenic activity of aFGF for a variety of target cells in culture, and to stabilize it from heat inactivation (II-21, II-22). Despite binding tightly to bFGF, heparin had minimal effects on its mitogenic activity (II-22). In view of the relatedness of KGF to the FGFs, the effect of heparin on KGF mitogenic activity was examined. As shown in Table II-1, thymidine incorporation by BALB/MK cells in response to KGF was inhibited 16 fold when heparin was included in the culture medium. In contrast, the activities of both aFGF and bFGF were increased by the same treatment.

Production of anti-KGF antibodies. Several kinds of antibodies which recognize KGF or KGF-like polypeptides have been prepared using standard methodologies well known in the art of experimental immunology and summarized in the Methods section, above. These include: monoclonal antibodies raised in mice against intact, purified protein from human fibroblasts; polyclonal antibodies raised in rabbits against synthetic peptides with sequences based on amino acid sequences predicted from the KGF cDNA sequence; polyclonal antibodies raised in rabbits against both naturally secreted KGF from

human fibroblasts and recombinant KGF produced in *E. coli* (see next section).

Monoclonal antibodies from three different hybridomas have been purified. All three recognize the recombinant as well as the naturally occurring KGF in a solid-phase (ELISA) assay. None cross-reacts with KGF under denaturing conditions (in a Western blot), and none neutralizes mitogenic activity of KGF in the BALB/MK bioassay.

Polyclonal antibodies were generated with a synthetic peptide with the amino acid sequence NDMTPEQMATNVR, corresponding to residues numbered 32 through 44 in KGF (see Fig. II-1), plus an R (arg) residue instead of the actual asp residue encoded by the cDNA at position 45. The asp residue is probably glycosylated in the natural KGF polypeptide and, therefore, appeared to be an arg in the amino acid sequencing data obtained directly from that polypeptide (see Discussion, below). Polyclonal antibodies generated with this synthetic peptide recognize both naturally occurring and recombinant KGF in ELISA and Western blot analyses at a level of sensitivity of at least as low as 10 ng protein. These antibodies, however, do not neutralize mitogenic activity of KGF in the BALB/MK bioassay.

Polyclonal antisera against intact natural KGF protein recognizes KGF in both ELISA and Western blot assays. Such antibodies also appear to inhibit mitogenic activity of KGF in the BALB/MK bioassay.

Expression of KGF cDNA in *E. coli*. KGF cDNA was expressed to produce polypeptide in *E. coli* by placing its coding sequence under control of the hybrid trk promoter (comprising elements of trp and lac promoters), in the plasmid pKK233-2 (II-31). To accomplish this, a specific length of KGF cDNA that contained the information to code for the mature KGF molecule (i.e., without its signal peptide) was amplified using the polymerase chain reaction technique (II-32). The fragment was directionally inserted between two sites in the vector, namely the *Nco*I site, made blunt ended by *S*1 nuclease digestion, and the *Hind*III site, using standard recombinant DNA methodology. Selected recombinants were sequenced at their cDNA 5' ends to ensure correct alignment of the ATG initiation codon with the regulatory elements of the trk promoter.

Several recombinants were tested for protein production by the usual small scale methods. In brief, the clones were grown to mid-exponential phase ($OD_{595} \sim 0.5$), treated with 1 mM

isopropanol β -D-thiogalactopyranoside (IPTG) for 90 minutes, and cell extracts were run on SDS-polyacrylamide gels for Western blot analysis.

All recombinants tested synthesized a protein that was recognized by antibodies raised against an amino-terminal KGF peptide. One recombinant was selected which showed the greatest induction from IPTG, for further protein analyses.

One liter of bacteria was grown up in NZY broth containing 50 μ g/ml ampicillin and 12.5 μ g/ml tetracycline, to OD_{595} 0.5, and treated for 90 min. with IPTG. The cells were collected by centrifugation, resuspended in 50 mM sodium phosphate (pH 7.3), 0.2 M NaCl, and lysed by sonication. Cell debris was removed by centrifugation, and lysate applied directly to a heparin-Sepharose affinity column.

As determined by Western blot analysis and mitogenic activity in keratinocytes, recombinant KGF was eluted in 0.5-0.6 M NaCl. Subsequent purification of the HSAC material with a Mono-S (FPLC) column (Pharmacia) yielded a preparation of KGF estimated to be $\geq 90\%$ pure, as judged by electrophoretic analysis using SDS-polyacrylamide gels and silver-staining.

Recombinant KGF efficiently stimulated thymidine incorporation into BALB/MK keratinocyte cells, but was only marginally active on NIH/3T3

fibroblasts. Half-maximal stimulation of the BALB/MK cells in the standard keratinocyte bioassay was achieved with a concentration of between 2 to 5 ng/ml, compared to a concentration of 10 to 15 ng/ml for KGF purified from M426 cells. One liter of bacterial cells yielded approximately 50 µg of Mono-S purified recombinant KGF.

Construction of a chimera containing KGF and aFGF sequences. The studies above indicated that KGF possessed two distinctive characteristics which might be encoded by distinct portions or domains of the polypeptide sequence, as is well known to occur in coding sequences of other multifunctional polypeptides. To test this possibility, a chimeric DNA segment encoding the NH₂-terminal sequence of KGF grafted onto the C terminal core of aFGF was constructed, as follows. A *Sau3AI* restriction enzyme site (GATC) in the 5' end of the KGF cDNA, within codons for residues 78 and 79 (arg and ile, respectively; see Fig. II-2) was cut and joined to an homologous site in the aFGF cDNA within codons for amino acids 39 (arg) and 40. The 3' and 5' ends of this chimeric DNA were joined to the vector DNA of the plasmid pKK233-2 by the same method used for insertion of the KGF cDNA

encoding the secreted form of polypeptide (see Methods, above).

When recombinant *E. coli* cells were constructed using the vector carrying the chimera, and expressions tests were conducted as described for mature KGF, above, a novel product with properties of both KGF and aFGF was produced. The peptide was enriched by heparin-Sepharose chromatography and found to have a target cell preference for keratinocytes, like KGF, with minimal activity on fibroblasts (NIH/3T3). The mitogenic activity of this chimeric polypeptide lacks, however, susceptibility to inhibition by heparin, a characteristic which parallels that of aFGF rather than KGF. In fact, the mitogenic activity on keratinocytes is actually enhanced by heparin, as is the case for aFGF. Thus the peptide domains responsible for cell target specificity and heparin sensitivity are clearly distinct and readily separable in KGF, according to the practice of the present invention.

DISCUSSION

The experiments described in this section illustrate the practice of several principal embodiments of the present invention. These include isolation of cDNAs encoding KGF,

expression of such cDNAs in recombinant cells;
production of various antibodies reactive with
KGF, and construction and expression of a
chimeric cDNA encoding a novel growth factor with
5 amino acid sequences and related functionalities
of both KGF and aFGF. The following points
related to these embodiments may also be noted to
enhance the understanding of the present
invention.

10 The sequence predicted from the KGF cDNA
agreed with the amino acid sequence determined
from the purified KGF form secreted by human
fibroblasts. Moreover, the sequence offered
potential explanations for positions where
15 definitive amino acid assignments could not be
made by direct amino acid sequencing. Residues
32 and 46 are predicted from the cDNA sequence to
be cysteines, and hydrolyzed derivatives of
unmodified cysteine residues are not detectable
20 following Edman degradation. The predicted KGF
amino acid sequence also contained one potential
N-linked glycosylation site (Asn-X-Ser/Thr) from
residues 45 through 47. If Asn 45 were
glycosylated, it would not be detected by the
25 amino acid sequencing methods employed here. In
fact, KGF migrates as a broad band on
NaDodSO₄/PAGE at a higher molecular weight than

predicted for the purified protein. It may be accounted for by glycosylation.

The FGFs are heparin-binding mitogens with broad target cell specificities (II-10).

5 The *hst* gene was identified as a transforming gene from a human stomach tumor (II-11), adjacent normal stomach tissue (II-12), and from Kaposi's sarcoma (II-13), by standard NIH/3T3 transfection assays. The product of the *int-2* gene is expressed
10 normally during mouse embryogenesis (II-14) and aberrantly after proviral integration of mouse mammary tumor virus (II-15).

KGF is the sixth member of the fibroblast growth factor family to be identified
15 (II-28). While the name FGF-6 does not seem suitable because KGF is devoid of activity on fibroblasts, this nomenclature may also be used for this growth factor, to denote its structural relationship to the FGF family. As all
20 previously characterized growth factors either exclude epithelial cells as targets or include them among a number of sensitive target cells, the highly specific nature of KGF mitogenic activity for epithelial cells, and the
25 sensitivity of keratinocytes in particular, make it unique.

In studies to date, expression of the KGF transcript appears to be specific for stromal cells derived from epithelial tissues, suggesting its function in normal epithelial cell proliferation. The availability of the KGF cDNA clone will make it possible to determine whether abnormal expression of this growth factor can be implicated in clinical conditions characterized by epithelial cell dysplasia and/or neoplasia. Moreover, the ability to produce large quantities of this novel growth factor by recombinant techniques should allow testing of its clinical applicability in situations where specific growth of epithelial cells is of particular importance.

Alignment of the KGF sequence with the five other proteins of the FGF family revealed two major regions of homology, spanning amino acids 65-156 and 162-189 in the predicted KGF sequence, which were separated by a short, nonhomologous series of amino acids with varying lengths in different members of the family. A topographical comparison of the FGF family of related molecules is provided in Fig. II-2. The two protein domains that share high homology are shown by shaded boxes. Hatched boxes indicate putative signal peptide sequences. The positions of two conserved cysteine residues (C) are shown. In the case of *int-2*, the length of this nonhomologous sequence was 17 residues, while in *hst*, the two homologous regions were contiguous. In KGF the intervening sequence consisted of five amino acids.



In the aligned regions, the *hF* amino acid sequence was about 44% identical to *int-2* (mouse), 39% identical to bFGF (human), 37% identical to aFGF (human) and 33% identical to *hst* (human). In this same region, all six proteins were identical at 19% of the residues, and allowing for conservative substitutions, they showed 28% homology.

As shown in Fig. II-2, the amino termini of these related proteins are nonhomologous and of variable length. The primary KGF and *hst* translation products contain hydrophobic N-terminal regions which likely serve as signal sequences (II-16). The fact that this N-terminal domain is not present in the mature KGF molecule (Fig. II-1B) further supports this conclusion. In contrast, the FGFs are synthesized apparently without signal peptides (II-10). The *int-2* protein contains an atypically short region of N-terminal hydrophobic residues (II-17), but it is not known if the protein is secreted. Moreover, the *int-2* protein contains a long C-terminal extension compared to the other family members.

Purified KGF contains five cysteine residues, two of which are conserved throughout the family of FGF related proteins (Fig. II-2). Also of note are the five pairs of basic residues

throughout the KGF sequence. This same pattern has been observed in other FGF family members and may be involved in their interaction with heparin (II-18). Dibasic sites are also common targets
5 for proteolytic processing and such processing might account for the microheterogeneity observed in some KGF preparations (unpublished data).

The KGF cDNA sequence was AT rich throughout its length, but particularly so in the
10 3' untranslated region where the AT content was 70% as compared to 60% in the putative coding sequence and 63% in the 5' untranslated region. The 3' untranslated region contained a large number of ATTTA sequences, which have been
15 proposed to be involved in the selected degradation of transiently expressed, unstable RNAs (II-19). There was no classical AATAAA polyadenylation signal but two variant sequences, AATTAA and AATACA (II-20), were detected 24 and
20 19 nucleotides, respectively, upstream of the poly(A) sequence at the 3' end of the cDNA.

It has been suggested that the heparin effect on acidic FGF is either due to stabilization of the active conformation of the
25 growth factor or to formation of a tertiary complex with acidic FGF and its receptor (II-21, II-22). If so, heparin may stabilize a conformation of KGF that is not as active as the

free molecule, or form a tight complex that is unable to efficiently interact with its receptor.

While its ability to bind heparin reflects the structural similarities of KGF with the FGF's, the differences in target cell specificities between these related mitogens is remarkable. The FGF's induce division of most nonterminally differentiated cells of both embryonic mesodermal and neuroectodermal origin.

10 In addition to fibroblasts and vascular endothelial tissues, mesodermally derived targets in culture include myoblasts, chondrocytes and osteoblasts (II-23). FGF's are also mitogenic for glial astrocytes and neuroblasts (II-24).

15 The product of the oncogene isolated from Kaposi's sarcoma, which is identical to *hst*, also stimulates proliferation of NIH/3T3 and capillary endothelial cells (II-25). To date, KGF induced mitogenesis has only been observed in epithelial

20 cells, and the absence of any detectable activity in fibroblasts or endothelial cells has also been demonstrated (see Experimental Section I, above and II-3). It seems likely, therefore, that KGF acts through a different cell surface receptor

25 than the FGFs.

There is no significant N-terminal homology between KGF and other FGF-related proteins. Thus, the construction of chimeric

molecules between KGF and a prototype aFGF was undertaken to determine whether the KGF N-terminal domain is sufficient to account for its unique target cell specificity. The results on the first such recombinant polypeptide sequence indicate that the N-terminal domain of KGF essentially encodes the cell preference for keratinocytes, while the susceptibility of KGF to heparin is encoded somewhere in the C-terminal core region which was replaced by sequences of aFGF. This novel KGF-like growth factor may have advantages in clinical applications where administration of an epithelial-specific growth factor is desirable in the presence of heparin, a commonly used anticoagulant. Additional studies on chimeras should also provide insights into which specific domains in the C-terminal core contribute the different effects of heparin on their biologic activities.

20

REFERENCES FOR EXPERIMENTAL II

- II-1. James, R. and Bradshaw, R. A. (1984)
Ann. Rev. Biochem. 53, 259-292.
- II-2. Sporn, M. B. and Todaro, G. J. (1980) *N. Eng. J. Med.* 303, 878-880.
- 25 II-3. Rubin, J. S., Osada, H., Finch, P. W.,
Taylor, W. G., Rudikoff, S. and

- Aaronson, S. A. (1989) *Proc. Natl. Acad. Sci. USA* (in press).
- II-4. Crick, F. H. C. (1966) *J. Mol. Biol.* 19, 548-555.
- 5 II-5. Ohtsuka, E., Matsuki, S., Ikehara, M., Takashi, Y. and Matsubara, K. (1985) *J. Biol. Chem.* 260, 2605-2608.
- II-6. Miki, T., Matsui, T., Heidaran, M. and Aaronson, S. A. (1989) *Proc. Natl. Acad. Sci.* (in press).
- 10 II-7. Aaronson, S. A. and Todaro, G. J. (1968) *Virology* 36, 254-261.
- II-8. Kozak, M. (1987) *Nucl. Acids Res.* 13, 8125-8148.
- 15 II-9. Lipman, D. J. and Pearson, R. W. (1985) *Science* 227, 1435-1441.
- II-10. Thomas, K. (1987) *FASEB J.* 1, 434-440.
- II-11. Taira, M., Yoshida, T., Miyagawa, K., Sakamoto, H., Terada, M. and Sugimara, T. (1987) *Proc. Natl. Acad. Sci. USA* 84, 2980-2984.
- 20 II-12. Yoshida, T., Miyagawa, K., Odagiri, H., Sakamoto, H., Little, P. F. R., Terada, M. and Sugimara, T. (1987) *Proc. Natl. Acad. Sci. USA* 84, 7305-7309.
- 25 II-13. Delli-Bovi, P. and Basillico, C. (1987) *Proc. Natl. Acad. Sci. USA* 84, 5660-5664.

- II-14. Jakobovits, A., Shackelford, J. M.,
Varmus, H. E. and Martin, G. R. (1986)
Proc. Natl. Acad. Sci. USA **83**, 7806-7810.
- 5 II-15. Peters, G., Brookes, S. and Dickson, S.
(1983) *Cell* **33**, 364-377.
- II-16. von Heijne, G. (1986) *Nucl. Acids Res.* **14**,
4683-4690.
- 10 II-17. Moore, R. Casey, G., Brookes, S., Dixon,
M., Peters, G. and Dickson, C. (1986)
EMBO J. **5**, 919-924.
- II-18. Schwarzbauer, J.E., Tamkun, J.M.,
Lemischka, I. R. and Hynes, R. O. (1983)
Cell **35**, 421-431.
- 15 II-19. Shaw, G. and Kamen, R. (1986) *Cell* **46**,
659-667.
- II-20. Birnsteil, M. L., Busslinger, M. and
Strub, K. (1985) *Cell* **41**, 349-359.
- 20 II-21. Schrieber, A. B., Kenny, J., Kowalski,
W., Friesel, J., Mehlman, T. and Maciag,
T. (1985) *Proc Natl. Acad. Sci. USA* **82**,
6138-6142.
- II-22. Gospodarowicz, O. and Cheng, J. (1986)
J. Cell Physiol. **128**, 475-485.
- 25 II-23. Thomas, K. A. and Gimenez-Gallego, G.
(1986) *Trends Biochem. Soc.* **11**, 81-84.

- II-24. Gensburger, C., Labourdette, J. and Sensembrenner, M. (1987) *FEBS Lett.* 217, 1-5.
- 5 II-25. Delli-Bovi, P, Curatola, A M., Kern, F. G., Greco, A., Ittman, M. and Basilico, C. (1987) *Cell* 50, 729-737.
- II-26. Sanger, F., Nicklen, S. and Coulson, A. R. (1977) *Proc. Natl. Acad. Sci. USA* 74, 5463 5467.
- 10 II-27. Yanisch-Perron, C., Vieira, J. and Messing, J. (1985) *Gene* 33, 103-119.
- II-28. Zhan, X., Bates, B., Hu, X. and Goldfarb, M. (1988) *Mol. Cell. Biol.* 8, 3487-3495.
- 15 II-29. Abrahams J. A., Mergia, A., Whang, J.L., Tumolo, A., Friedman, J., Hjerrild, K. A., Gospodarowicz, D. and Fiddes, J. C. (1986) *Science* 233, 545-548.
- 20 II-30. Mansour, S. L. and Martin, G. R. (1988) *EMBO J.* 1, 2035-2041.
- II-31. Amman, E. and Brosius, J. (1985) *Gene* 40, 183.
- 25 II-32. Sakai, R. K., Scharf, S., Faloona, F., Mullis, K.B., Norn, G.T., Erlich, H.A. and Arnheim, N. (1985) *Science* 230, 1350-1354.

- II-33. Beckman, P.M., Betsholtz, C. Meldin, C-
H., Westermark, B. DiMarco, E., DiFiore,
P.P., Robbins, K.C. and Aaronson, S. A.
(1988) *Science* **241**, 1346-1349.

For purposes of completing the background description and present disclosure, each of the published articles, patents and patent applications heretofore identified in this specification are hereby incorporated by reference into the specification.

The foregoing invention has been described in some detail for purposes of clarity and understanding. It will also be obvious that various combinations in form and detail can be made without departing from the scope of the invention.

Table 1-1. Growth Factor Purification.

Purification step	Protein (mg)	Total activity (units)	Specific activity (units/mg)
Conditioned medium (10 liters)	1.4×10^{-3a}	2.5×10^4	1.8×10^1
Ultrafiltration (retentate)	1.3×10^{-3a}	3.2×10^4	2.5×10^1
MSAC 0.6 M NaCl pool	0.73^b	1.6×10^4	2.2×10^4
TSK-G3000 SW	8.4×10^{-3b}	2.7×10^3	3.2×10^5
C ₄ -MPLC	6.1×10^{-3b}	2.1×10^2	3.4×10^4

Recoveries were calculated by assuming that all of the mitogenic activity in the starting material was due to the isolated factor.

5 One unit of activity is defined as half of the maximal stimulation of thymidine incorporation induced by TSK-purified factor in the BALB/MK bioassay, in which approximately 3 ng of the TSK-purified factor stimulated 1 unit of activity.

10 ^a Protein was estimated by using the Bradford reagent from BioRad (I-23).

^b Protein was estimated by using $A_{214}^{1\%} = 140$.



Tabl I-2. Target Cell Specificity of Growth Factors

Growth Factor	<u>Epithelial</u>			<u>Fibroblasts</u>	<u>Endothelial</u>
	BALB/3T3	BS/589	CCL208	NIH/3T3S	Human saphenous vein
KGF	500-1000	2-3	5-10	<1	<1
EGF	100-200	20-40	10-30	10-20	n.d.
TGF α	150-300	n.d.	n.d.	10-20	n.d.
aFGF*	300-500	2-3	5-10	50-70	5
bFGF	100-200	2-3	2-5	50-70	5

Comparison of maximal thymidine incorporation stimulated by ~~KGF~~ and other growth factors in a variety of cell lines, expressed as fold stimulation over background.

- 5 This data represents a summary of four different experiments.

* Maximal stimulation by aFGF required the presence of heparin (Sigma), 20 μ g/ml.

n.d. = not determined.



THE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS:

1. A substantially pure human keratinocyte growth factor (KGF) protein or KGF-like protein having a molecular weight between 16 and 30 kDa as determined by migration in NaDodSO₄/PAGE, and having a specific activity of at least about 3.4×10^4 units per milligram of protein, wherein the minimum amount of growth factor sufficient to stimulate maximum mitogenic activity in cells of epithelial origin does not stimulate mitogenic activity in fibroblasts.
2. A protein according to claim 1 which is glycosylated.
3. A protein according to claim 1 having all or a portion of the amino acid sequence in Figure II-1B.
4. A protein according to claim 3 which lacks the signal peptide sequence in Figure II-1B.
5. A protein according to claim 1 which is not glycosylated.
6. A chimeric KGF-like protein which comprises within a single polypeptide molecule functional domains of human KGF according to any one of claims 1 to 5 and at least one other polypeptide of the fibroblast growth factor family.
7. A chimeric KGF-like protein according to claim 6, wherein the fibroblast growth factor polypeptide is acidic fibroblast growth factor (aFGF).
8. A chimeric KGF-like protein according to claim 7, wherein the functional domain from KGF is defined by amino acid residues responsible for the preferential mitogenic activity of KGF on epithelial cells and the functional domain from aFGF that is defined by amino acid residues in that portion of aFGF that is homologous to the KGF sequence responsible for heparin sensitivity of KGF.
9. A chimeric KGF-like protein according to claim 8, wherein said functional domain from KGF is defined by amino acid residues numbered 39 through 78 in Figure II-1B and said functional domain from aFGF is defined by about 140 amino acid residues comprising the carboxyl terminus of



aFGF, beginning at residue number 39.

10. A pharmaceutical composition comprising a chimeric KGF-like protein according to any one of claims 6 to 9, and an acceptable pharmaceutical carrier.

5 11. A method for treatment of conditions requiring specific stimulation of epithelial cells in the presence of heparin comprising administering an amount of the composition of claim 10 sufficient to stimulate epithelial cells.

10 12. An antibody directed against all or a portion of human KGF or KGF-like protein, according to claim 3.

13. An antibody according to claim 12 which neutralizes the mitogenic activity of human KGF.

15 14. An antibody according to claim 12 which is polyclonal antibody.

15. An antibody according to claim 12 which is monoclonal antibody.

20 16. DNA encoding a human keratinocyte growth factor (KGF) protein or KGF-like protein having a molecular weight between 16 and 30 kDa as determined by migration in NaDodSO₄/PAGE, wherein the minimum amount of growth factor sufficient to stimulate maximum mitogenic activity in cells of epithelial origin does not stimulate mitogenic activity in fibroblasts.

25 17. DNA according to claim 16, which encodes all or a portion of the amino acid sequence defined in Figure II-1B or the complementary strand to said DNA.

30 18. DNA according to claim 17 which lacks the nucleotide sequence encoding the signal peptide sequence indicated in Figure II-1B or the complementary strand to said DNA.

19. DNA comprising all or a portion of the nucleotide sequence in Figure II-1B or the complementary strand to said DNA.

35 20. DNA encoding a chimeric KGF-like protein which comprises within a single polypeptide molecule functional domains according to any one of claims 1 to 5 of human KGF



and at least one other polypeptide of the fibroblast growth factor family or the complementary strand to said DNA.

21. DNA according to claim 20, wherein the fibroblast growth factor polypeptide is acidic fibroblast growth factor (aFGF) or the complementary strand to said DNA.

22. DNA according to claim 21, wherein the functional domain from KGF is defined by amino acid residues responsible for preferential mitogenic activity of KGF on epithelial cells and the functional domain from aFGF that is defined by amino acid residues in that portion of aFGF that is homologous to the KGF sequence responsible for heparin sensitivity of KGF or the complementary strand to said DNA.

23. DNA according to claim 21, wherein said functional domain from KGF is defined by amino acid residues numbered 39 through 78 in Figure II-1 and said functional domain from aFGF is defined by about 140 amino acid residues comprising the carboxyl terminus of aFGF, beginning at residue number 39 or the complementary strand to said DNA.

24. A recombinant DNA molecule comprising DNA according to any one of claims 16 to 23 and a vector.

25. A recombinant DNA molecule according to claim 24, wherein said vector is a plasmid, a bacteriophage cloning vector, a DNA sequencing plasmid vector, a bacterial gene expression vector, or a mammalian gene expression vector.

26. A culture of cells transformed with a DNA molecule according to any one of claims 16 to 23, or a recombinant DNA molecule according to claim 24 or claim 25.

27. A culture of cells according to claim 26, wherein said cells are prokaryotic cells or eukaryotic cells.

28. A bioassay for KGF-like activity, said activity being capable of stimulating maximum mitogenic activity in cells of epithelial origin without stimulating mitogenic activity of fibroblasts, in a test sample suspected to possess said activity, which comprises the following steps:



- i) growing keratinocytes in culture to confluence and maintaining said confluent culture in serum-free medium;
- ii) adding a test sample to said confluent culture of keratinocytes; and
- iii) determining the stimulation of DNA synthesis in said keratinocytes.

5

10

29. A method according to claim 28, wherein said step iii is carried out in the presence and absence of KGF neutralizing antiserum.

15

30. A method of producing all or a portion of human KGF protein or KGF-like protein comprising culturing the cells of claim 26 or claim 27 in a culture medium under conditions such that said protein is produced and isolating said protein from said cells.

20

31. A human KGF protein according to Figure II-1B wherein the N-terminus is at or about cysteine 32 and the C-terminus is at or about threonine 194.

25

32. A non-glycosylated human KGF protein or a portion thereof according to claim 1, said KGF protein having a molecular weight between 16-30 kDa as determined by migration in NaDodSO₄/PAGE and having a specific activity of at least about 3.4×10^4 units per milligram of protein, wherein the minimum amount of growth factor sufficient to stimulate maximum mitogenic activity in cells of epithelial origin does not stimulate mitogenic activity in fibroblasts.

30

33. A method of producing KGF or a KGF-like protein according to any one of claims 1 to 9, 31 or 32 from cultured cells comprising the following steps:

35

- i) culturing KGF-producing cells in culture medium under conditions such that KGF is produced;
- ii) lysing said cells, if necessary, to release intracellular KGF into the surrounding culture medium;



- iii) optionally concentrating said culture medium so that a first concentrate is formed;
- iv) contacting said concentrate with heparin under conditions such that KGF present in said first concentrate binds to the heparin whereby a heparin-KGF complex is formed;
- v) separating said heparin-KGF complex from said concentrate;
- vi) treating said heparin-KGF complex under conditions such that said KGF dissociates from the heparin so that a solution of free KGF is formed;
- vii) concentrating said solution so that a second concentrate is formed; and
- viii) fractionating said second concentrate so that KGF is separated from the remaining components.

34. A method of producing KGF or KGF-like protein from cultured cells, according to claim 30 or claim 33, wherein said KGF-producing cells are prokaryotic cells or eukaryotic cells.

35. The method according to claim 34 wherein said cells are E. coli cells.

36. A method for determining the level of a KGF RNA transcript encoding KGF protein or KGF-like protein according to any one of claims 1 to 5 comprising the steps of:

- i) isolating mRNA from tissues or cells;
- ii) annealing said RNA to a DNA probe encoding a human KGF or a portion of a human KGF; and
- iii) determining the amount of DNA:RNA hybrid containing said DNA probe.

37. A method for determining the level of KGF protein expression comprising reacting polypeptides from body fluids or tissue samples with an antibody specific for a



peptide having the amino acid sequence of human KGF or KGF-like protein, according to claim 12, and determining the amount of protein-antibody binding.

5 38. A research reagent comprising all or a portion of KGF protein according to any one of claims 1 to 9, 31 or 32, and optionally a physiologically acceptable culture fluid.

10 39. A method of stimulating epithelial cell growth in vitro comprising adding an amount of the reagent of claim 38 sufficient to stimulate epithelial cell growth.

40. A method according to claim 39 wherein said cells are keratinocytes.

41. Host cells transfected with a recombinant DNA molecule according to claim 24 or 25.

15 42. The cells of claim 41 wherein said cells are prokaryotic cells or eukaryotic cells.

43. The cells of claim 42 wherein said cells are E. coli transfected with a bacterial expression vector.

20 44. An antibody of claim 12 which reacts against the peptide NDMTPEQMATNVR.

45. A pharmaceutical composition comprising at least one antibody according to claim 12 and a pharmaceutically acceptable carrier.

25 46. A pharmaceutical composition comprising at least one protein or peptide according to any one of claims 1 to 9, 31 and 32 and a pharmaceutically acceptable carrier.

30 47. A method for treatment of conditions requiring specific stimulation of epithelial cells comprising administering an amount of the composition of claim 46 sufficient to stimulate epithelial cell proliferation.

48. A method for treatment of conditions according to claim 47 in which said treatment involves acceleration or improvement of wound healing involving the epidermis.



49. A method for treatment of conditions requiring
specific inhibition of stimulation of epithelial cells by
KGF comprising administering an amount of the composition
of claim 45 sufficient to inhibit epithelial cell
5 stimulation by KGF.

DATED THIS 28TH DAY OF JANUARY 1994

JEFFREY S. RUBIN; PAUL W. FINCH and
STUART A. AARONSON
10 By Its Patent Attorneys

GRIFFITH HACK & CO
Fellows Institute of Patent
Attorneys of Australia






FIG. 2A




FIG. 2C





FIG. 2B



19 20 21 22 23 24 25 26
FRACTION NUMBER

FIG. 3




FIG. 4




FIG. 5(a)

FIG. 5(b)

FIG. 5(c)

FIG. 5(d)









FIG. 5(e)

FIG. 5(f)

FIG. 5(g)

FIG. 5(h)

FIG. 6A




FIG. 6B(1)

FIG. 6B(2)

```

1  ACGCGCTCACACACAGAGAGAGAAAATCCTTCTGCCTGTTG
121 GCACCAGGCAGACAACAGACATGGAATTCTTATATATCC
241 TTATCAACAGAGTTATTTAAGGAGGAATCCTGTGTTGTT

361 AAGAGGTCAATGACCTAGGAGTAACAATCAACTCAAGAT

481 L L Y R S C F H I I C L V
   TTTGCTCTACAGATCATGCTTTTCACATTATCTGTCTAGT

601 T R S Y D Y M E G G D I R
   CACAAGAAGTTATGATTACATGGAAGGAGGGGATATAAG

721 N N Y N I M E I R T V A V
   GAATAATTACAATATCATGGAAATCAGGACAGTGGCAGT

841 C N E D C N F K E L I L E
   ATGCAATGAAGATTGTAACCTTCAAAGAACTAATTCTGGA

961 P V R G K K T K K E Q K T
   TCCTGTAAAGAGGAAAAAAACGAAGAAAGAACAAAAAAC

1081 TGGACTGTTTTCTTTCTTCTCAAAAATTTTCTTTCTTTT
1201 ACACTGCATTAAAGAAAGATTTGAAAAGTATACACAAAAA
1321 TAAATTTAATTTACCCCTTAAGAGTATGTTAGATTTTGATTA
1441 GGTATATCAGACCTACAGGCTTCTGGCAGGATTTTGTCAG
1561 AATCAGAAAAAAATTTCTCAAAAAAACTATTATGAAAGT
1681 TCAAGTGGAAAGGGTATTGCTAAAAGGATGTTTCCAAAAA
1801 CCTCAAAGTAAATTTGAGAAATCTTTTAAGTTTTTTTCAA
1921 TTCCTATGGTTACAGCATTAACACTCTATTTTAAGTTGTT
2041 TTTTAAATTTTAAAGGAATAACAAAACCTGTCTGGCTCAAC
2161 ATAAGAGCCTGAAGCAATGCTTACAATAGATGTCTCACA
2281 ATATAAGTATTTACAGGATTTTAAAGTTAGAATATATTT
2401 TGTTCAAAAGGTGGCAGCACTGAAAGTTGTTTTCTGTT
2521 CCTACAGATAACAGGATTATTACAAGGATGAATTTCCAC
2641 GTATGCTAACCACCTGTGGTTTTAATTTCAAATATTTGT
2761 CAATAGATTTCATTTAATTTTCTGTGGTTGACCTATACG
2881 CACCTGATTCAAGGACTTTGCTAGCTAGGTTTTTGAGGTC
3001 GCAGACTATCTGTTTCATAATCAGTTTTTCAGTGTGAATTC
3121 TTTAAATAGAAAATAGTGATATACATATAAAATACAAGCT
3241 ATTTAGTGGTAAATCCATTTCCTGGTAGTATAAGTCACCT
3361 AAATTTGCTCTAGTTACACACCTTTTGAATTTCTAGAATA
3481 GCTGGGTAGATATACAGCTGTCACAAGAGTCTAGATCAG
3601 AGATATAGCCTTTACATTTGTACACAAATGTGACTATGT
3721 TCAATTCTGATTCTATTCACCTTTTGTATTATGAATGGA
3841 TCTAACAAATTAGAAAAAAACAAAAAAACAAAAAAAC

```

FIG. 6B(2)

9/13
FIG. 6B(2)

FIG. 6B(1)

FIG. 6B(3)

ATTTATGGAAACAATTATGATTCTGCTGGAGAACTTTT
AGCTGTTAGCAACAAAACAAAAGTCAAATAGCAAACAG
ATCAGGAACTAAAAGGATAAAGGCTAACAATTTGGAAAG

TCATTTTCATTATGTTATTCATGAACACCCGGAGCACT

30

G T I S L A C N D M T P
GGGTACTATATCTTTAGCTTGCAATGACATGACTCCAG

70

V R R L F C R T Q W Y L
AGTGAGAAGACTCTTCTGTGCGAACACAGTGGTACCTGA

110

G I V A I K G V E S E F
TGGAATTGTGGCAATCAAAGGGGTGGAAAGTGAATTCT

150

N H Y N T Y A S A K W T
AAACCATTACAACACATATGCATCAGCTAAATGGACAC

190

A H F L P M A I T *
AGCCCACTTTCTTCCTATGGCAATAACTTAATTGCATA

ATTTTTTTAGTAATCAAGAAAGGCTGGAAAAACTACTGA
ATCAGATTTTAGTAACATAAAGGTTGTAAAAAATTGTAAA
TCTGATAATGATTATTTAAATATTCTATCTGCTTATA
ATAATCAAGCCACACTAACTATGGAAAAATGAGCAGCAT
CAATAAAATAGATAATTTAACAATAAGTACAGGATTAGA
ATCTTGTATATAAGATAGCAACAGTGATTGATGATAAT
GTAAACATAATCTATCTTTGTATAATTTCATATTTGGGAA
TTTGAACTTTATTGTTTTGTTATTTAAGTTTATGTTAT
GGCAAGTTTTCCCTCCCTTTTCTGACTGACACTAAGTCT
CAACAACAATACAAATATGTAAAAACTCTTTTCAACCACAT
GAATGCATGGGTAGAAAAATATCATATTTTAAAACTATG
AGATGGCAAGAGCACAATGCCCAAAATAGAAGATGCAG
TTCAAAAAGTCTTTTCATTGGCAGATCTTGGTAGCACTTT
CATTCAAGTCCCTTTTACATAAATAGTATTTGGTAATAC
ACCAGGATGTAGAAAACTAGAAAGAACTGCCCTTCCTC
AGGCTTTCAGTAACTGTAGTCTTGTGAGCATATTGAGGG
ACTGAATGTTTATAGACAAAAGAAAATACACACTAAAA
ATGTTAGGACCATAATGCTCTTTGTCTATGGAGTTATAC
AAAAAAGACTTCTAGAAATATGTACTTTAATTATTTGT
TTAAACACTGTAAGGGGCCCTCCATCCCTCTTACTCATTT
TTAGCACATGCTTTCTACTCTTTCGATTATTAGTATTAT
CTTGGCAATGCACTTTCATACACAATGACTAATCTATAC
AAGCTTTGTGCAAAATATACATATAAGCAGAGTAAGCC

FIG. 6B(1)

FIG. 6B(3)

FIG. 6B(3)

FIG. 6B(2)

CAGCTGAGAAATAGTTTGTAGCTACAGTAGAAAGGCTCAAGTT
 CGTCACAGCAACTGAACTTACTACGAACTGTTTTTATGAGGAT
 AGCAAGTACTCTTTCTTAAATCAATCTACAATTCACAGATAGG

ACACTATAATGCACAAATGGATACTGACATGGATCCTGCCAAC

E Q M A T N V N C S S P E R H
 AGCAAATGGCTACAAATGTGAAGTGTCCAGCCCTGAGCGACA

R I D K R G K V K G T Q E M K
 GGATCGATAAAAGAGGCAAAGTAAAAGGGACCCAAAGAGATGAA

Y L A M N K E G K L Y A K K E
 ATCTTGCAATGAACAAGGAAGGAAAAGTCTATGCAAAGAAAGA

H N G G E M F V A L N Q K G I
 ACAACGGAGGGGAAATGTTTGTTCCTTAAATCAAAAGGGGAT

TGGTATATAAAGAACCCAGTTCCAGCAGGGAGATTTCTTTAAG

AAAAGTATGATCAAGCTGGACTTGTGCATTTTATGTTTGTITTTAAG
 ACTGGTTGTACAATCATGATGTTAGTAACAGTAATTTTTTTCT
 AAATGGCTGCTATAATAATAATAATACAGATGTTGTTATATAA
 TTTAAATGCTTTCTAGTGAAAAATTATAATCTACTTAAACTCT
 ACATGCTTATACCTATAAATAAGAACAAAATTTCTAATGCTGC
 ACTGTACTTTCATCTTACTTGCACAAAATAACATTTTATAAAT
 TATGGCTTTTAAATAATGTTCTTCCCACAAAATAATCATGCTTTT
 TTATAAAAAAACCCTTAATAAGCTGTATCTGTTTTCATATGC
 AGCACACAGCACTTGGGCCAGCAAATCCTGGAAGCAGACAAAAA
 ATTCTTGCCAATTAAATTGGATCATATAAGTAAAATCATTACAA
 TATATTTTAAATTTAGTAATTTTCTAATCTCTAGAAATCTCTGC
 TTAAGAATAAGGGGCCCTGAATGTCATGAAGGCTTGAGGTCAG
 ATATGTTTCAACAATGGGAGGTCAATATTTATCTAATTTAAAAG
 ATTTATAGATGAGAGTTATATGAAAAGGCTAGGTCAACAAAAA
 AGATATAGTCTTGGGAGAGAGCATGAATGGTATTCTGAAGTAT
 CAGAGGAGGACTTAGTTTTTTCATATGTGTTTCTTAGTGCCTA
 CTAATCTTCAATTTTAAAAGGGTAAAACATGACTATACAGAAAT
 TTCCATCAAAATTACATAGCAATGCTGAATTAGGCCAAAAACAAC
 TTTTCTCCTATTTTTTAAATTTTATTTATGCAAATTTTAGAAAAA
 GTAGTCTAGGAAATTTGAGATTTTGTATACACCTAAGGTCAACGCA
 TAGCTAATGGTCTTTGGCATGTTTTTGTTTTTTTATTTCTGTTG
 TGTGATGATTTGACTCAAAAGGAGAAAAGAAATTTATGTAGTTT
 TTTTAAAAATGTTCTTTGAAAGATAAATTAATAACATGAGTT

FIG. 6B(2)

FIG. 6C




FIG. 7





FIG. 8



INTERNATIONAL SEARCH REPORT

International Application No. PCT/US90/00418

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) * According to International Patent Classification (IPC) or to ~~other~~ National Classification and 1976 IPC(5): c07K 3/18,13/00,7/06,7/08,7/10;C12N 5/00,15/50; G01N 33/536						
II. FIELDS SEARCHED Minimum Documentation Searched ? <table style="width: 100%; border: none;"> <tr> <td style="width: 20%; border: none; vertical-align: top;"> Classification System </td> <td style="border: none; vertical-align: top;"> Classification Symbols </td> </tr> <tr> <td style="border: none; vertical-align: top;"> U.S. </td> <td style="border: none; vertical-align: top;"> 530/399,387,324-329,413; 435/320,240.1;436/536 </td> </tr> </table> Documentation Searched other than Minimum Documentation to the extent that such Documents are included in the Fields Searched *			Classification System	Classification Symbols	U.S.	530/399,387,324-329,413; 435/320,240.1;436/536
Classification System	Classification Symbols					
U.S.	530/399,387,324-329,413; 435/320,240.1;436/536					
Chemical Abstracts Service 7 Registry, Sequence Search, Automated Patent Search						
III. DOCUMENTS CONSIDERED TO BE RELEVANT †						
Category *	Citation of Document, † with indication, where appropriate, of the relevant passages ‡	Relevant to Claims ‡				
X Y	EMBO Journal, V.5 (5) pp 919-924, "Sequence, to pography and protein coding potential of mouse <u>int-2</u> : a putative oncogene activated by mouse mammary tumor virus " (Moore) May 1986, See abstract & figure 2.	1-6,11,15-19 23-25 12-14				
X,P	Nucleic Acids Research, V.17(F) p 286F "The nucleotide sequence of rat heparin binding growth factor-1" (Goodrich) 11 April 1989 See entire article.	11,16-18 12-14				
A	Pro. Natl. Sci. uSA, V.82 pp 6507-6511 Primary Structure of Bovin pituitary basic fibroblast growth factor "(Esch) October 1985, See entire article	1-31				
A	US, A, 4,444,760 (Thomas) 24 April 1984 See entire document.	1-31				
X A	US, A, 4,743,679 (Cohen) 10 May 1988 See claim 6 and Abstract.	1-2 1-31				
A	Cell, V. 38 p 287-297 "Human Transforming growth factor- " (Derynck) August 1984 See entire article	1-31				
Y	Immunology pgs. 110-113" Biological aspects of the immune Response" (Barrett, 3rd ED.) 1978	12-14				
* Special categories of cited documents: † "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step "Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. "A" document member of the same patent family						
IV. CERTIFICATION						
Date of the Actual Completion of the International Search 23 APRIL 1990		Date of Mailing of this International Search Report 10 MAY 1990				
International Searching Authority ISA/US		Signature of Authorized Officer: NINA OSSANNA				